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Ras is the most frequently mutated oncogene in human cancers. It acts as a critical branch 
point in signal transduction, regulating numerous downstream effectors involved in cell 
growth and differentiation. While Ras has the capacity to activate many growth 
promoting pathways, it can paradoxically regulate growth inhibitory pathways leading to 
apoptosis and cell cycle arrest. One of the ways Ras can inhibit the growth of cells is via 
a family of effectors called the RASSF proteins. One of the members of this family, 
RASSF5, also known as Novel Ras Effector 1A (NORE1A), is a tumor suppressor that is 
frequently inactivated in human tumors by epigenetic mechanisms. NORE1A binds 
directly to Ras, and it promotes the growth inhibitory properties of Ras by activating a 
tumor suppressive function called oncogene induced senescence. We have recently 
shown in the laboratory that NORE1A serves as a senescence effector of Ras by 
activating the p53 tumor suppressor. However, knockdown of p53 using siRNA 
technology did not completely abrogate the ability of NORE1A to induce senescence, 
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suggesting that there may be additional mechanisms by which NORE1A promotes 
senescence. The other well characterized pathway involved in Ras-induced senescence is 
the Rb pathway. Using immunoprecipitation techniques, we show that NORE1A forms 
an endogenous, Ras regulated complex with the Rb phosphatase PP1A, and that 
Ras/NORE1A promote the stability of the PP1A protein. Furthermore, our results show 
that NORE1A scaffolds PP1A to Rb in a Ras dependent manner, in turn promoting the 
dephosphorylation of Rb, a pro-senescent event. Using western blot analysis, we found 
that NORE1A can also regulate non-phosphorylation post-translational modifications of 
Rb, including its acetylation and SUMOylation. Using commercially available 
senescence detection kits, we found that loss of Rb significantly suppressed the ability of 
NORE1A to induce senescence in both murine and human systems. Collectively, our 
work strongly suggests that NORE1A is a double barreled Ras senescence node, 
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BACKGROUND AND INTRODUCTION 
 
1.1 – Overview: 
 
 Cancer is the second leading cause of death among Americans, only after heart 
disease (1). More importantly, one of every four deaths in the United States is due to 
cancer (2). This disease is projected to reach healthcare costs of over 200 billion dollars 
by 2020 (3), highlighting the urgency not only for improved cancer therapies, but 
discovering novel and innovative treatments for currently undruggable cancers. 
Ultimately, the solution may lie in unraveling the complexities of cancer progression and 
gaining a better understanding of tumor development. 
 It is widely believed that in order for a normal cell to transform into a cancer cell, 
genes that regulate growth and differentiation must be altered. Cancer can be caused by 
alterations in oncogenes, tumor suppressor genes, and microRNAs (4). It was 
hypothesized over thirty years ago that cells contain proto-oncogenes, genes that are 
involved with normal aspects of behavior, and that such proto-oncogenes might be 
mutated to give rise to oncogenes. In turn, these oncogenes have the ability to convert 
normal cells into cancer cells (5). 
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Some of the most significant and well-characterized proto-oncogenes in human 
cancer are the three Ras proto-oncogenes. Mutations in one of these three genes can give 
rise to a constitutively active Ras protein. Such mutations can be a critical step in tumor 
initiation and development, because aberrant Ras signaling will continuously activate 
downstream effector pathways involved in growth, differentiation, and cell survival (6). 
Recent advances in genetic technology have enabled researchers to examine the true 
significance of Ras in cancer: over one third of all human cancers contain activating point 
mutations in the Ras gene (7). From an oncogenic standpoint, Ras can regulate numerous 
growth promoting pathways, including the classic trio of Ras effector pathways Raf, 
phosphoinositide 3-kinase (PI3K), and ral guanine nucleotide dissociation stimulator 
(RalGDS) (7-9). Furthermore, functional studies have shown that at least six Ras effector 
signaling pathways are involved in either the initiation or the maintenance of Ras driven 
cancers (10). 
However,  counterintuitive evidence dating as far back as the early 1980s pointed 
to the notion that Ras does not exclusively promote the growth of cells (11). It has now 
become clear that while oncogenic Ras can promote transformation by regulating 
numerous growth promoting pathways, Ras can paradoxically promote apoptosis and 
senescence (12). However, the mechanisms by which Ras can inhibit the growth of cells 
are poorly understood. More recent evidence has implicated the RASSF family of tumor 
suppressors as negative effectors of Ras (13). RASSF5, or Novel Ras Effector 1A (which 
from this point forward will be referred to as NORE1A), was the first identified member 
of the RASSF family, and has been shown to bind directly to Ras (14) in order to activate 
Ras mediated growth inhibitory pathways. More importantly, loss of NORE1A 
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expression due to epigenetic mechanisms can be found in a variety of different tumors 
(15), supporting its role as a tumor suppressor. 
Initial evidence of NORE1A acting as a tumor suppressor was quite strong. First, 
transient over-expression of NORE1A can lead to apoptosis (16). Second, restoring 
NORE1A expression in a NORE1A negative cell line was shown to inhibit its 
transforming phenotype (17). And in some cases, restoring NORE1A expression in 
tumors that have lost NORE1A expression can significantly diminish the tumorigenic 
phenotype (16). This work, along with data showing that the dysregulation of NORE1A 
is implicated in a rare familial cancer syndrome (18), confirms that NORE1A is a bona 
fide tumor suppressor. While NORE1A has now been shown to have powerful tumor 
suppressive functions, in part by regulating the p53 and HIPPO tumor suppressor 
pathways (12,19,20), the significance of NORE1A as a negative effector of Ras is only 
partially understood. 
Recent evidence showed that NORE1A is critical senescence effector of Ras, in 
part by activating the pro-senescent post-translational modifications of p53 (20). But, in 
addition to p53, Ras can promote senescence by activating the Retinoblastoma (Rb) 
protein, a tumor suppressor believed to be inactivated directly or indirectly in virtually all 
human cancers (21).  Rb is primarily activated by dephosphorylation, and phosphatases 
such as PP1A promote the activation of Rb by dephosphorylation (22). Interestingly, 
PP1A was detected in complex with NORE1A in a yeast two-hybrid screen (23). Using 
state of the art biological techniques, including immunoprecipitations, western blot 
analysis, luciferase assays, and senescence assays, we sought out to determine if Ras 
could regulate Rb via its effector NORE1A. The collective work and data depicted in this 
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dissertation highlights the discovery of a novel signaling pathway by which Ras and 
NORE1A cooperate to suppress growth by activating the tumor suppressive functions of 
Rb, in turn promoting the onset of cellular senescence. Here, we will show that NORE1A 
can bind to and stabilize PP1A. This interaction is significantly enhanced by Ras, in turn 
allowing PP1A to activate Rb by promoting its dephosphorylation, a pro-senescent event 
(24). Furthermore, we show that NORE1A requires Rb in order to fully promote its 
senescent function. 
This work identified a further mechanism by which NORE1A can promote 
oncogene induced senescence caused by activated Ras. After characterizing the role of 
NORE1A mediated dephosphorylation of Rb, we decided to investigate the potential for 
NORE1A to alter additional post-translational modifications of Rb. Initial experimental 
work found that Ras/NORE1A enhanced the total levels of Rb acetylation, currently 
thought to be an activating event, in part by maintaining Rb in its active, de-
phosphorylated state. We go on to show that Ras/NORE1A can also modulate the 
SUMOylation of Rb. While the biological significance of this Rb modification remains 
unclear, this is the first line of evidence showing that Ras can regulate the SUMOylation 
of downstream targets using effector proteins such as NORE1A. 
We also present evidence that, in addition to affecting the post-translational 
modifications of Rb, NORE1A also seems to stabilize Rb. Thus, we identify a novel 
function for NORE1A, acting as a Ras regulated scaffolding molecule to enhance PP1A 
binding to Rb to promote its activation, in turn promoting the induction of senescence. 
This finding could have a significant impact, based on the notion that, depending 
on its regulatory molecules, PP1 can form stable complexes with as many as 650 
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mammalian proteins (25). Furthermore, we have provided evidence suggesting that Ras 
can regulate both the acetylation as well as the SUMOylation machinery, in addition to 
its proto-typical ability to affect protein function by phosphorylation and de-
phosphorylation events. These additional findings could have major ramifications as to 
how Ras can regulate protein function on multiple levels, and that the code of post-
translational modifications regulated by Ras could have adverse effects on protein 
localization, stabilization, and activity. 
 
1.2 – The Ras Oncogene: 
 
 The Ras genes may be the most well characterized oncogenes in human cancer 
(26). High frequency of Ras mutations occurs in a wide spectrum of human cancers, 
including three of the four most deadly cancers in the US (lung, colon, and pancreatic 
cancer) (27), highlights the importance of Ras as an integral component of tumorigenesis. 
Here, we provide a chronology of the most important discoveries regarding Ras protein 
structure and function, the activation and regulation of Ras, the mechanisms of Ras signal 
transduction, both growth promoting and tumor suppressive, and its implications in 
cancer. 
 
1.2.1 – The Discovery of Ras: 
 
 The identification of Ras emerged during the extensive study of acutely 
transforming retroviruses from mice, rats, cats, and chickens (28). The path to the 
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discovery of Ras began in 1964, when Jennifer Harvey discovered that preparing a 
murine leukemia virus, obtained from a leukemic rat, and injecting it into newborn 
rodents would induce sarcomas (29). The Kirsten-MSV (murine sarcoma virus) was 
identified in 1967 by serial passaging of murine leukemia viruses through Wister-Furth 
rats (30). It was not until 1975 that Scolnick et al. showed that these viral strains were 
recombinant viruses that carry sequences derived from the rat genome. These findings, 
work that many at the time thought to be irrelevant to human cancer, provided the first 
line of evidence of what were termed oncogenic genetic elements (28). Unfortunately, the 
realization that human cancers are not initiated by transforming retroviruses dampened 
enthusiasm. 
 These genes, termed Ras for rat sarcoma virus, were identified in the human 
genome in 1982. Three groups made the simultaneous discovery that transforming genes 
introduced by DNA transfection assay into NIH/3T3 cells were the same Ras genes 
identified earlier in the Kirsten and Harvey sarcoma viruses (31-33), and that the 
transforming effects were caused by a missense mutation in the Ras gene (34-37). 
Furthermore, the identification of mutant Ras genes in patient tumors but not in normal 
tissues was an important validation that the Ras mutations identified in cell culture were 
not just artifacts of cell passaging in vitro (28). While these discoveries were critical for 
unraveling the concept that mutations can turn proto-oncogenes into oncogenes and in 
turn play a significant role in tumor development, they fail to address how Ras functions, 





1.2.2 – Ras and Cancer: 
 
 As the most commonly mutated oncogene in cancer, Ras has been thought of as 
the “Holy Grail” of cancer drug development (38). Early experimental work was slow 
and complicated due to the fact that Ras is controlled through several different positive 
and negative regulators and can act upon numerous downstream effectors, each with a 
defined pattern of tissue-specific expression and distinct set of intracellular functions. 
Initial investigations to understand the roles of activated Ras showed that oncogenic 
alleles contained a very specific set of point mutations. 
 Mammalian Ras genes acquire transformation-inducing properties by single point 
mutations with their coding sequences. Mutations in naturally occurring Ras oncogenes 
have been localized in codons 12, 13, 59, and 61 (37). In addition, in vitro mutagenesis 
studies have shown that mutations in codons 63, 116, and 119 can also confer 
transforming properties to Ras genes (39-41). Interestingly, the presence of a glycine 
residue at position 12 appears to be necessary for the normal function of Ras proteins, as 
it has been shown that substitution of Gly-12 by any other amino acid (with the exception 
of proline) results in the oncogenic activation of Ras (42). Second, substitution of Gly-13 
also has transforming consequences for the harboring cells, though not all substitutions 
appear to have the same activating effect (39,43). Third, substitution of Gln-61 by any 
other amino acid residue, except Pro-61 and Glu-61, yields oncogenic Ras (44). The 
effects of other point mutations of Ras are less understood, though have been shown to 
turn Ras into an oncogene. Unlike the retroviral Ras oncogenes, which exhibit two 
mutations, all cellular Ras oncogenes only carry a single activating mutation (45). By 
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1983, all three members of the Ras family had been identified (46). Similar to H-Ras and 
K-Ras, the newly identified N-Ras was also found to contain activating point mutations 
in certain human tumors (47).  
After the initial discovery of the Ras oncogene, reports began to surface noting 
that certain types of human cancers were specifically associated with a small number of 
specific mutations in the reading frame of the Ras gene. The most frequent Ras mutations 
are found in K-Ras, and they are frequently observed in pancreatic (48) and colon cancers 
(49). Second, N-Ras mutations were primarily associated with lymphoid malignancies 
(43,50-53) and melanomas (54). Lastly, H-Ras mutations were mostly associated with 
bladder carcinomas (55), though such mutations are found much less frequently 
compared to K- and N-Ras mutations. It was later found that mutations in Ras occur in 
approximately one third of all human tumors, with the highest incidence in the pancreas 
(90%), colon (50%), thyroid (50%), lung (30%) and leukemia (30%) (56). 
 
1.2.3 – Regulation of Ras Activation: 
 
 Once the significance of Ras in cancer was discovered, work began to shift 
towards understanding how Ras functions to promote cancer and how it can be regulated. 
Ras proteins have since then been shown to bind guanine nucleotides and possess 
intrinsic GTPase activity (57). The biochemical properties of Ras proteins closely 
resemble those of the G proteins involved in the modulation of signal transduction 
through transmembrane signaling systems (58). The bound guanine moiety determines 
the activity of G proteins: when a G protein is bound to a GTP molecule, the protein is 
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typically in the active conformation. However, heterotrimeric G proteins were known to 
possess an intrinsic GTP hydrolysis activity (which from this point forward will be 
referred to as GTPase activity) (Figure 1). Thus, in order to regulate its activity, the G 
protein will hydrolyze GTP into GDP, in turn shuttling itself into an inactive 
conformation. This on/off switch is critical for the proper regulation of G proteins such as 
Ras, and reactivation occurs when the GFP is exchanged for a GTP molecule, which is 
typically more abundant in the cell (57). 
 Further evidence showed that mutations of the Ras gene can cause the Ras 
oncoprotein to behave differently than their normal counterparts (59-61). The observation 
that many oncogenic mutants of Ras are reduced in GTPase activity led to the initial 
belief that Ras mediated transformation occurred as a result of the impaired intrinsic 
GTPase activity of Ras (59-62); however, this theory would eventually be proven wrong. 
Analysis of GTPase activities associated with a large number of Ras mutants failed to 
reveal a quantitative relationship between GTPase activity and transforming potential 
(44,63-65). The notion that mutant Ras was only about 8-fold less active than wild-type 
Ras had many speculating if this was sufficient to account for its transforming power 
(66). Work performed by Trahey and McCormick went on to show that a GTPase 
activating protein (GAP) allows normal Ras proteins to turn themselves off efficiently by 
greatly enhancing the GTPase activity of Ras, whereas oncogenic Ras proteins stay 
locked in the active, GTP-bound form (67). Contrary to the initial hypothesis, it is the 
resistance to GAPs that leaves Ras proteins permanently GTP bound. Thus, the resistance 






Figure 1: Model for Ras Activation. Mitogenic stimuli, such as growth factors, can 
regulate the activity of Ras, which is predominantly found on the inner leaflet of the 
plasma membrane. Ras can act as a critical branch-point in signal transduction: the GTP-
bound form is active while the GDP-bound form is inactive. GTP loading caused by 
guanine nucleotide exchange factors (GEFs) induces a conformational change in Ras that 
allows it to bind effectors via their Ras-binding domains. In its GTP-bound form, Ras 
interacts with and regulates numerous downstream effectors, such as MAPK. Ras can be 
inactivated by its intrinsic GTPase activity, which can be accelerated by the binding of 
GTPase activating proteins (GAPs). This converts GTP back to GDP, returning Ras to 
the off conformation. 
<http://medicinembbs.blogspot.com/2011/02/essential-alterations-for-malignant.html> 
Copyright Permissions not required for this type of use. 
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1.2.4 – Post-Translational Modifications of Ras: 
 
 Extensive work using deletion mutants of mammalian Ras genes has led to the 
identification of the carboxyl terminal sequence Cys
186
-A-A-A-X-COOH (68). 
Interestingly, it was shown around that time that Ras proteins have been localized to the 
inner side of the plasma membrane (69). More importantly, mutants lacking Cys-186 
code for proteins that remain in the cytosol and cannot induce transformation of NIH3T3 
cells, suggesting that this post-translational modification is required for the proper 
biological function of Ras (70). Interestingly, blocking C-terminal modifications of 
human H-Ras using C-terminal antibodies impaired normal GTP-binding function (71), 
validating the notion that the C-terminal processing and subsequent recruitment of Ras to 
the membrane is required for proper Ras function. 
 Even though the Ras family members show some differences in sequence 
homology in the C-terminus, it has been shown that they all contain a consensus CAAX 
sequence at the C-terminus (72-74), where C is a cysteine residue, A is aliphatic, and X is 
any amino acid (75). This C-terminal domain acts as a key regulator of Ras function, in 
part by playing a role in proper localization of Ras to the inner leaflet of the plasma 
membrane (76). The mechanism and sequence of events for Ras localization to the cell 
membrane was elucidated in the early 1990s. First, a farnesyl pyrophosphate group is 
covalently attached to a cytosolic Ras protein by an enzyme called farnesyltransferase 
(77-79). Second, Ras-converting enzyme 1 (RCE1) causes a proteolytic cleavage of the 
last three amino acids of Ras. Third, isoprenylcysteine carboxyl methyltransferase 1 
(ICMT1) methylates the last Cysteine residue. And lastly, an enzyme called 
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palmitoyltransferase (PTase) transfers an additional palmitoyl group to the Cysteine 
residue upstream of the C-terminus, in turn allowing for proper insertion of Ras into the 
inner cell membrane (80). 
 As was the case with the complexity of GTPase regulation of Ras activity, the 
post-translational modifications of Ras proteins involved in recruitment of Ras to the cell 
membrane were also not straight-forward. Further evidence pointed to additional 
mechanisms for full recruitment of Ras to the cell membrane (80). Some isoforms of Ras 
(including H-Ras, N-Ras, and K-Ras 4A) required additional palmitoyl groups to be 
attached to the C-terminal cysteine residue before being able to be attached to the cell 
membrane; however, K-Ras-4B does not have any palmitoylation at all, but rather 
contains a string of positively charged Lysine residues (known as the polybasic region) 
found upstream of the C-terminus that are sufficient to attach Ras to the membrane (81).  
 
1.2.5 – Growth Promoting Pathways of Ras: 
 
 The discovery of Ras behaving as a critical oncogene to drive cancer development 
dates back to the early 1980s. This led to an onslaught of research to try and understand 
the biological processes that are regulated by Ras. Studies done in 1984 showed that 
treatment with epidermal growth factor (EGF) led to an increase in the GTPase activity of 
H-Ras (82). This was the first line of evidence pointing to Ras being involved in 
regulation of growth pathways. These findings, along with other work implicating Ras 
regulation by other growth factors and cytokines, suggest that just like prototypical G 
proteins, Ras can behave as a signal transduction molecule (83-86). The GTP-bound form 
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of Ras is in the active form by virtue of its increased affinity for effectors; more 
importantly, there are at least eleven distinct classes of Ras effectors that have so far been 
identified (10), with the majority of these effectors possessing either Ras-binding 
domains (RBD) or Ras-association (RA) domains (87). Association with Ras-GTP 
promotes effector activation by increasing the concentration of effectors at the plasma 
membrane, where additional events facilitate activation or enhance catalytic activity (10). 
 The role of Ras in signal transduction was largely undefined in the early to mid 
1980s, though it had clearly been established as a regulator of cell growth and 
differentiation. However, work done by Bar-Sagi and colleagues in 1986 showed that 
microinjection of Ras protein into rat embryonic fibroblasts led to a significant increase 
in the activation of phospholipase A (88), an enzyme known to hydrolyze phospholipids 
into fatty acids and is involved in the production of arachinodic acid. Further work led to 
the concept of Ras effector signaling pathways: evidence shown in 1988 by Fukami et al. 
demonstrated that inhibition of phosphatidylinositol 4,5-bisphosphate (PIP2) caused 
reversible and dose-dependent decrease in proliferation and reversion of cell morphology 
of Ras-transformed cells (89). Furthermore, work performed by Feramisco and 
colleagues implicated the kinase Raf as a downstream effector of Ras, though the 
connection between Ras and Raf was not defined (82). Due to the development of yeast 
two-hybrid technology, it was later shown that the interaction between Ras and Raf was 
direct (90). This was the first true line of evidence implicating Ras in signal transduction, 
suggesting that Ras is directly interacting with its effector proteins to regulate 
downstream signaling cascades. As a whole, Ras regulates numerous growth promoting 
pathways, including the Raf/MEK/Erk, PI3K/AKT, and the Ral-GDS pathways 
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(collectively known as the classical Ras pathways). The Ras effector signaling pathways 
are critical for Ras biology, and ongoing efforts over the past thirty years have begun to 
decipher the molecular web of Ras signaling. 
 
1.2.5.1 – Raf/MEK/Erk Pathway: 
 
 The first Ras effector pathway to be identified was the RAF-MEK-Erk pathway 
(90-93). Activation of the pathway begins with Ras activation. Classically, an 
extracellular signal binds to a protein tyrosine kinase receptor, such as epidermal growth 
factor receptor (EGFR) or the platelet-derived growth factor receptor (PDGFR), in turn 
inducing the oligomerization of the receptor (94). This leads to the allosteric activation of 
the intracellular tyrosine kinase (95,96), resulting in the cross-phosphorylation of the 
receptors. The phospho-tyrosines in the intracellular domain can now serve as docking 
sites for adaptor proteins (97). Adaptor proteins such as Grb2 can now recognize SH2 
domains and recruit guanine-nucleotide exchange factors (GEFs), such as Sos, to the 
membrane (98). The GEF is able to activate membrane-associated Ras by converting it 
from its inactive GDP-bound form to its active GTP-bound form. GTP binding promotes 
a conformational change permitting Ras to associate with downstream effectors. Raf is 
then recruited to the cell membrane and is activated via its interaction with Ras (99). 
 Raf is the best characterized Ras effector and is considered an oncogene in its 
own right. Raf is a member of a family of serine/threonine kinases that include Raf-1, A-
Raf and B-Raf. Raf activation by Ras stimulates a kinase cascade by phosphorylation of 
MAPKK (also called MEK in mammalian systems), in turn activating downstream 
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proteins Erk1 and Erk2 (MAPK). Activation of kinases Erk1 and Erk2 by MEK can 
phosphorylate and activate a number of nuclear transcription factors, other kinases, 
among many other proteins. Interestingly, many of the MEK/Erk targets have been 
implicated in Ras-induced cellular transformation (100). 
 For many years, the Raf oncogenes were not thought to be frequently mutated in 
human cancer, as aberrant activation of the Raf pathway was dedicated to Ras mutations, 
which can regulate both the Raf and the PI3K pathways (101). More extensive studies 
have now shown that it is not necessary to have mutated Ras in order to have aberrant 
Raf signaling. Recent work has shown that B-Raf is reported to be mutated in 
approximately 7% of all cancers, and is commonly found in melanoma (~30 to 70%), 
thyroid cancer (~35 to 50%), colorectal cancer (~5 to 20%), and ovarian cancer (~30%) 
(102). 
 While it is clear that Raf is a critical effector of Ras and is involved in Ras 
mediated cellular transformation via MEK/Erk, activation of the Raf proteins is very 
complex as there are many phosphorylation sites on Raf, and Raf activation/inactivation 
depends in large part on its phosphorylation status (101). While the kinases involved in 
the regulation of the Raf/MEK/Erk pathway have been extensively studied, the 
knowledge of phosphatases involved in these regulatory events remains poorly 
understood. In addition, it has now been shown that Raf has roles outside of the canonical 
MEK/Erk downstream effectors, some of which involve the prevention of apoptosis. To 
make matters more complicated, it has been shown that the Raf/MEK/Erk pathway can 
paradoxically effect cell cycle arrest differentiation, and senescence (103,104). Thus, the 
Raf/MEK/Erk pathway seems to have some opposing functions, adding to the complexity 
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of its regulation. What is clear is that Raf is a critical downstream effector of Ras by 
binding directly to Ras; furthermore, Raf preferentially binds to the active, GTP bound 
form of Ras, further validating the role of Raf as a bona fide Ras effector (93). 
 
1.2.5.2 – PI3K/AKT Pathway: 
 
 One of the best characterized Ras effector families is the PI3K family, of which 
the members play important roles as mediators of Ras mediated cell survival and 
proliferation (105,106). The PI3K family of enzymes is organized into 3 main classes 
(class I, II, and III). Interestingly, Ras is able to interact with the different isoforms of 
class I PI3Ks, which is the most well characterized family and the one most clearly 
implicated in human cancer (107). PI3-kinase catalyzes the conversion of 
phosphatidylinositol 4,5-bisphosphate (PIP2) to phosphatidylinositol 3,4,5-triphosphate 
(PIP3), which binds the pleckstrin homology (PH) domain of Akt, stimulating its kinase 
activity (108). Akt activation controls signaling pathways regulating different cellular 
processes such as cell survival, glucose uptake, and glycogen metabolism. Specifically, 
Akt promotes cell survival primarily by inhibiting the pro-apoptotic Bcl-2 family 
members BAD and BAX (109,110). Second, Akt can promote an increase in transcription 
of anti-apoptotic and pro-survival genes by negatively regulating the transcription factor 
NF-κB (111). Third, Akt can phosphorylate Mdm2, an event that antagonizes p53-
mediated apoptosis (108). In addition to Akt activation, PI3K can also activate the Rac 
GTPase, an important mediator of oncogenic Ras transformation (112). 
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 Although the importance of Ras proteins in developmental processes is clear, the 
oncogenic potential of constitutively activated Ras proteins and its implication in cancer 
has drawn far more attention. Interestingly, aberrant PI3K signaling is one of the most 
frequent occurrences in human cancer (110,113). In addition, it has been shown that PI3K 
signaling is indispensable to maintain transformed growth in Ras mutant cell lines both in 
vitro and in xenografts in mice. Although multiple Ras effectors are essential to initiate 
tumor formation, only signaling through the PI3K/Akt pathway seems to be necessary to 
maintain tumor growth (114). By increasing the ability for growth and by decreasing the 
capacity for apoptosis, PI3K signaling supports tumorigenesis. More importantly, mice 
with mutations in the PI3K catalytic subunit p110α, which blocks its ability to interact 
with Ras, are highly resistant to endogenous oncogenic K-Ras-induced tumorigenesis and 
H-Ras-induced skin carcinogenesis (106,108). 
 The Ras/PI3K pathway has also been implicated in cancer metastasis, the leading 
cause of death in cancer patients. Ras activates Rac via PI3K, and Rac regulation of actin 
reorganization and membrane ruffling can promote increased cell motility and contribute 
to tumor cell invasion and metastasis (115). Furthermore, oncogenic Ras and PI3K can 
promote the loss of anchorage-dependent growth, which is a key feature needed for tumor 
cells to form metastases (116-118). 
 
1.2.5.3 – Ral-GDS Pathway: 
 
 The third classical Ras effector pathway involves the Ral-GEF proteins. RalGEF 
members (RalGDS, RGL, RGL2, and RGL3) link Ras proteins to activation of the RalA 
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and RalB small GTPases (119). Activation of Ral allows it to interact with its 
downstream effectors, including Sec5, RalBP1, and ZONAB, though it is likely that there 
are additional protein partners not yet identified. Through these interactions, Ral proteins 
can regulate a wide array of cellular functions, such as proliferation, migration, and 
vesicle sorting (120). Ral can also control gene expression through transcription factors 
like fos, jun, AFX, and ZONAB. 
RalGDS was discovered in 1994 in a yeast two-hybrid screen performed in 
multiple labs (121). RalGDS was found to catalyze nucleotide exchange on both RalA 
and RalB, but not on other small GTPases such as the Ras, Rho, and Rab families (122). 
Therefore, activation of RalGDS by Ras ultimately results in the activation of Ral. 
Activated Ral can in turn bind to several downstream effectors involved in critical 
biological processes, including actin organization, cytokinesis, autophagy, gene 
transcription, cell proliferation, cell survival, and secondary messenger production (122). 
The biological function of RalGDS, as well as the other Ral-GEF family 
members, is not fully understood, although there is evidence that they play an important 
role in Ras mediated transformation in vivo (123,124). Work performed by Gonzalez-
Garcia and colleagues showed that mice lacking RalGDS show reduced tumor incidence, 
size, and progression in a skin cancer model where H-Ras was the primary driver (124). 
They went on to show that RalGDS was required for skin tumor formation through 
mediation of JNK/SAPK pathway.  
Collectively, the initial evidence pointed to the idea that the activation of the Ral 
pathway alone has a weak oncogenic effect, but can complement the roles of other Ras 
effectors in promoting cell transformation in tissue culture (124). However, it has 
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recently been argued that the role of the Ral pathway in Ras dependent transformation 
could be more critical in human cells compared to rodent fibroblasts. When work 
performed by Counter and colleagues explored the role of Ral in Ras mediated growth 
transformation of immortalized human astrocytes, fibroblasts, or epithelial cells, a more 
prominent role for Ral GTPases as effectors of Ras in human cancer was observed (125). 
More importantly, work done by Hamad and colleagues made the striking observation 
that of the three best studied Ras effectors – Raf, PI3K, and RalGEF – that RalGEF was 
the most important in inducing human cells to proliferate in suspension (125). This result 
was unexpected because previous experiments in mouse cells had identified Raf as the 
most oncogenic (120). Ultimately, the evidence points to the RalGDS pathway as playing 
a far more significant role in human systems. While a lot of uncertainty remains in how 
RalGDS directly functions in Ras mediated transformation, Ral GTPase signaling has 
now emerged as being critical in both normal and neoplastic cell physiology (122). 
 
1.2.5.4 – Additional Ras Pathways: 
 
 Apart from the above-mentioned Ras effectors, an increasing number of 
molecules that specifically interact with Ras have been described (108). Some of the 
additional Ras effectors identified include phospholipase C, T-Cell lymphoma invasion 
and metastasis 1 (TIAM1), and Ras interaction/interference 1 (RIN1), all of which add 
complexity and significance for Ras in signal transduction and cellular transformation. 
 The ground-breaking work of Illenberger and colleagues was the first line of 
evidence implicating small GTPases in inositol lipid signaling (126,127). Additional 
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work went on to show that there are at least three different PLC isozymes (PLC-β2, -γ2, 
and -ɛ) that are robustly activated by Ras (128), though it seems that PLCɛ  may be the 
one most implicated in Ras mediated transformation. PLCɛ is a key mediator of calcium 
signaling, in part via the activation of Protein Kinase C (PKC) which allows for the 
release of calcium from the endoplasmic reticulum (128). Interestingly, recent evidence 
has provided a link between PLCɛ and tumor development. It has been shown that PLCɛ 
deficient mice are resistant to skin tumor formation in a chemical carcinogen-induced 
model (129). Additional evidence also points to PLCɛ increasing tumor formation by 
increasing important inflammatory responses in dermal fibroblasts (130). In addition to 
its link with tumorigenesis, there is now evidence showing that PLCɛ contains a CDC25 
domain, also referred to as a RasGEF domain, theoretically placing PLCɛ upstream of 
Ras, suggesting a potential positive feedback loop for PLCɛ signaling (131). As a whole, 
the work involving the Ras/PLCɛ pathway has shown its importance in signal 
transduction and tumor development. While PLCɛ has been shown to contain two C-
terminal RA domains and binds directly to Ras (132), many questions still remain 
unanswered as to the potential mechanisms by which it directly affects Ras mediated 
transformation. 
 T-Cell lymphoma invasion and metastasis-inducing 1 (TIAM1), a Rac-specific 
guanine nucleotide exchange factor, was first identified for invasiveness in mouse 
leukemia cells (133). It mediates a broad range of cellular processes, including cellular 
migration and adhesion (134). It has been reported that over-expression of TIAM1 is 
correlated with poor prognosis in patients with hepatocellular carcinoma (135), and 
additional reports have now shown that alterations in TIAM1 expression/function may 
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contribute to tumorigenesis and carcinoma progression of common types of cancer (136-
139). Interestingly, TIAM1 preferentially associates with activated GTP-bound Ras 
through a Ras-binding domain; this was shown to promote the activation of Rac in a 
PI3K-independent manner (140). Just as with the Ras/PLCɛ pathway, the Ras/TIAM1 is 
not fully understood, though it is likely that Ras mediated activation of Rac via TIAM1 
will have important ramifications on a number of biological processes, such as motility, 
growth, and invasion. 
 The Ras interaction/interference 1 (RIN1) protein was initially identified as a Ras 
effector in 1991 (141), and was later shown to bind directly to Ras (142,143). Recent 
work done by Wang and colleagues has shown that RIN1 has high-affinity for binding to 
Ras and also demonstrated that this binding directly competes with Raf1 (144). Most 
striking was RIN1 could inhibit cellular transformation by activated mutant Ras, thereby 
distinguishing RIN1 from other Ras effectors that enhance transformation (144). In 
addition to competing with Raf for binding to Ras, it has been proposed that RIN1 also 
functions by promoting endocytosis of Ras-stimulating growth factor receptors, such as 
EGFR (145). Thus, it seems that RIN1 behaves as a tumor suppressor by negatively 
regulating Ras function. This hypothesis was validated by work showing that loss of 
RIN1 can be found in breast tumor cell lines and that restoring RIN1 expression blocked 
anchorage-independent growth in vitro and tumor formation in vivo (146). Collectively, 
this was a critical discovery, suggesting that RIN1 was the first identified Ras binding 
partner that could antagonize Ras mediated transformation (142). This was the first line 
of evidence suggesting that effector signaling pathways regulated by Ras do not 
exclusively promote cellular growth and transformation. 
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1.2.6 – Growth Inhibitory Pathways: 
 
 Recently, there has been an appreciation that Ras, and other oncogenes, 
paradoxically induce both pro- and anti-apoptotic signaling (147), and that the outcome 
of these contradictory signals greatly depends on the cell type and context (148). The 
balance of positive and negative signals depends on a number of different parameters, 
including kinetics, stoichiometry, availability of different binding partners, and activation 
of other similar or countervailing forces (148) (Figure 2). Currently, it is believed that in 
normal cells, a constitutively high level of activated Ras induces a protective, pro-
apoptotic response to prevent oncogenesis (148). However, oncogenic Ras is likely to 
promote growth and differentiation in cells that have lost functional growth inhibitory 
pathways. Thus, Ras activates contradictory intracellular pathways, depending on cell 
context, that modulate cell viability (149). 
 It has been known for quite some time that powerful, innate mechanisms exist that 
restrain oncogenic potential (147). The first line of evidence in favor of this theory, at 
least for Ras, was published in 1983, when Newbold and Overell showed that in normal 
cells, oncogenic Ras triggered a profound growth arrest resembling replicative 
senescence (11). However, Ras could transform these fibroblasts if the cells had been 
newly immortalized by carcinogens, validating the claim that Ras is protective against 
oncogenesis in normal cells but oncogenic in nature in transformed cells. Future work has 
now shed some light on how Ras negatively regulates growth. Though the mechanisms 
remain relatively unclear, Ras can regulate at least two growth inhibitory pathways: 


















Figure 2: Ras paradoxically regulates both growth promoting and inhibitory 
pathways. Oncogenic Ras, depending on the cell context and cell type, can regulate both 
pro-growth and tumor suppressive pathways. In many cases, Ras activates cell 
proliferation by regulating the Raf, PI3K, and RalGDS pathways to promote growth and 
differentiation. However, signaling via the negative Ras effectors, including the RASSF 
family and MST kinases, can lead to apoptosis, cell cycle arrest, and induction of cellular 
senescence. It is thought that the loss of these functional growth inhibitory pathways is 
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1.2.6.1 – Apoptosis: 
 
 The identification of RIN1 as a potential negative effector of Ras intensified 
research toward the potential of Ras negatively regulating the growth of cells. It has been 
shown that RIN1 binds to activated Ras with a similar affinity to that seen by Raf1, and 
that RIN1 can inhibit cellular transformation caused by activated Ras (144). Additional 
findings in the 1990s validated the notion that Ras may able to regulate growth inhibitory 
properties of cells. First, constitutive expression of oncogenic Ras in a number of cell 
lines, including Jurkat (human T lymphoblastoid cell line) and murine fibroblasts, 
rendered cells susceptible to apoptosis following suppression of protein kinase C activity 
(150,151). Second, di Jeso and colleagues showed that serum withdrawal induces 
apoptotic cell death in K-Ras transformed cells, but not in normal differentiated thyroid 
cells (152), suggesting that oncogenic Ras was directly involved in serum-depleted 
induced apoptosis. In addition, cells over-expressing Crk-II, an adapter protein that 
regulates Ras activation, undergo apoptosis after serum-deprivation in a Ras dependent 
manner (153). Therefore, induction of apoptosis by Ras may be an important factor in 
limiting the expansion of somatic cells that sustain oncogenic Ras mutations (149). 
 While several independent studies had clearly highlighted a novel role for Ras in 
the regulation of apoptosis, the molecular mechanisms by which Ras could activate 
apoptotic signals were not completely understood, though it was clear that the ultimate 
outcome of pro-apoptotic Ras signals depends greatly on the cell type and context (148). 
This claim was based upon the notion that the Raf pathway, initially shown to promote 
growth, can actually be either anti- or pro-apoptotic depending on the circumstances 
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(148). However, this remains somewhat controversial, and it is still quite unclear exactly 
how the Raf pathway can differentiate between pro and anti-apoptotic signals. Thus, the 
focus of Ras mediated apoptosis switched toward potential negative effectors of Ras, 
especially after the discovery of RIN1. Interestingly, not long after the identification of 
RIN1, another family of negative Ras effectors was discovered that was believed to be 
the missing link between Ras and growth inhibition: the RASSF family. 
 
1.2.6.2 – Ras-Induced Senescence: 
 
 Cellular senescence was first described over forty years ago by Hayflick and 
colleagues, who showed that normal cells had a limited ability to proliferate in culture 
(154). They described that the remaining cells, over many cell doublings, remained viable 
for many weeks, but failed to grow despite the presence of ample space, nutrients, and 
growth factors in the medium (155). A senescent cell is a cell that has exited the cell 
cycle permanently and is incapable of resuming proliferation, even upon mitogenic 
stimuli (156,157). Some of the key characteristics of senescent cells include a typical flat 
and enlarged morphology, many (but not all) cell types acquire resistance to certain 
apoptotic signals, altered gene expression, and other senescence markers, such as 
senescence-associated β-galactosidase positivity (155,158). An enormous breakthrough 
occurred in 1997, when Serrano and colleagues showed that ectopic expression of 
oncogenic Ras in normal fibroblasts resulted in a permanent cell cycle arrest and a drastic 
increase in senescent cells (159). This work eventually led to the concept that has since 
been named “oncogene induced senescence.” While oncogene induced senescence was 
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first seen upon ectopic expression of activated Ras, it was later shown that ectopic 
expression of other oncogenes, such as E2F1, Raf, mos, cdc6, and cyclin E had very 
similar effects (160-162). Collectively, the evidence strongly suggests that aberrant 
mitogenic signaling in primary cells could lead to permanent cell cycle arrest and cellular 
senescence; more importantly, recent studies have now clearly established the role of 
cellular senescence as a potential tumor suppressor mechanism in vivo (158). Thus, 
oncogene induced senescence is widely believed to be a critical fail-safe mechanism that 
has been developed to suppress cell proliferation caused by aberrant activation of onco-
proteins in normal cells (163). 
 The mechanisms by which oncogenic Ras can promote the induction of 
senescence are slowly being discovered, but are quite complex and remain unclear. 
Initially, one of the hallmarks of cells undergoing oncogene induced senescence was the 
involvement of the p53 and the Rb pathways (164) (Figure 3). Oncogenic Ras alone has 
been shown to transform primary mouse fibroblasts that are deficient for either functional 
p53 or Rb pathways (165,166). However, induction of senescence in human cells seems 
more complex: evidence suggests that activation of both the p53 and the Rb pathways is 
essential for induction of senescence in a variety of human cell strains (164), and this 
may be due in part because of potential for cross-talk between the two pathways in 
human cells. While both pathways have consistently been shown to be vital for the proper 
activation of the senescent phenotype, it is worth noting that recent work performed by 
Wei and colleagues has shown that Rb is clearly required in human cells for Ras to 
induce senescence (167,168). Ultimately, Ras-induced senescence is circumvented by 

















Figure 3: Pathways involved in oncogene induced senescence. Ras-induced 
senescence is thought to function as a critical barrier against aberrant Ras signaling that 
would normally promote uncontrolled cell growth. While the mechanisms involved in 
Ras-induced senescence are not fully understood, it is clear that Ras activates senescence 
via the p53 and Rb tumor suppressor pathways. Loss of these functional pathways allows 
Ras to bypass senescence induction and in turn promote transformation. 
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 While the understanding of the significance of oncogene induced senescence as a 
critical barrier for tumor development grew, the mechanisms by which it occurs remains 
elusive. Additional evidence collectively showed that Ras-induced senescence truly 
involved an intricate web of multiple signaling mechanisms, including ATM, Arf, p16, 
p38, and FOXO (169). However, all of these mechanisms still ended up merging toward 
the two classical senescence pathways, p53 and Rb. Even though there was compelling 
evidence that Ras was promoting the induction of senescence through the p53 and Rb 
pathways, there was very little evidence linking Ras directly to these pathways. The 
hypothesis was that, similar to Ras mediated apoptosis, Ras was able to regulate 
senescence induction through its potential negative effectors. This hypothesis remained 
hanging in the balance, until the discovery of the RASSF family of tumor suppressors. 
 
1.3 – The RASSF Family of Tumor Suppressors: 
 
 Evidence highlighting growth inhibitory functions of Ras pointed to the 
possibility that Ras may have unidentified negative effectors that regulate such functions. 
One of the ways this question was addressed was by performing large yeast two-hybrid 
screens as an attempt to discover novel binding partners of Ras. Ras contains several 
well-characterized binding domains, including the RBD and the RA domain. As a result, 
such two-hybrid screens would specifically focus on individual binding sites of Ras. In 
1998, a potential Ras effector was newly identified by Vavvas and colleagues, which they 
termed NORE1 for novel Ras effector 1 (14). Two years later, a large scale data base 
search led to a second potential Ras effector, called RASSF1 (170). Over time, the 
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RASSF family of tumor suppressors would emerge as critical negative effectors of Ras, 
with some of the members far better characterized than others.  
 
1.3.1 – Overview of the RASSF Family: 
 
 The RASSF (Ras-Association Domain Family) proteins belong to a family of 
tumor suppressor proteins that is comprised of ten members (RASSF1-10), each with 
multiple splice variants, with the exception of RASSF9 and 10 (171,172) (Figure 4). 
Currently, the direct association with oncogenic Ras has been observed for RASSF1A, 
5A, and 6 (12,173-175). RASSF5A (NORE1A) was the first member of the RASSF 
protein to be cloned (14), hence the name NORE1 for Novel Ras Effector 1. The race to 
characterize the functional role of this family officially began once they were shown to 
behave as tumor suppressors. 
 The Ras Association (RA) domain is a functional domain found in several crucial 
Ras effectors, such as RalGDS and AF-6 (176). This is one of the most important 
consensus binding sites for all of the RASSF family members. In addition to the RA 
domain, RASSF proteins have several functional domains that regulate association with 
other proteins. The Salvador-RASSF-Hippo (SARAH) domain plays a role in specific 
protein-protein interactions as well as the homo- and heterodimerization of RASSF 
isoforms (177). Some of the key associations of RASSF proteins via the SARAH domain 
involve downstream kinases MST1 and MST2 as well as the tumor suppressor Salvador 









Figure 4: Schematic representation of the 10 human members of the RASSF family 
of tumor suppressors. Highlighted are three functional domains: the diacylglycerol 
binding (DAG) domain, the Ras Association (RA) domain, and the Salvador-RASSF-
Hippo (SARAH) domain. These proteins do not have any apparent enzymatic activity 
and are thought to primarily act as scaffolding molecules to promote the formation of 
critical tumor suppressor complexes. Direct association with oncogenic Ras has only 
been observed for RASSF1A, 5A (NORE1A), and 6. A majority of these tumor 
suppressors are inactivated in a variety of different human cancers, primarily by promoter 
methylation. Figure adapted from the Atlas of Genetics and Cytogenetics in Oncology 
and Hematology.  
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associations with numerous molecules and determine the involvement of RASSF proteins 
in several biological pathways in order to carry out tumor suppressor functions (177). 
 Perhaps the most well characterized RASSF family member is RASSF1A. It was 
shown in 2000 that the 3p21.3 region of the human genome contained one or more tumor 
suppressors, because this region frequently suffers loss of heterozygosity in lung cancer 
(179). That same year, Damman and colleagues cloned a gene in this region that they 
called RASSF1 because it contained a putative RA domain (180). Differential promoter 
activity and alternative splicing can lead to seven different transcripts (RASSF1A-G), 
though the two major isoforms are RASSF1A and RASSF1C (180). Of note, RASSF1A 
is considered a bona fide tumor suppressor, as knockout of RASSF1A in mice promotes 
an enhanced rate of cancer development (181). Additional work showed that RASSF1A 
is frequently inactivated by epigenetic mechanisms in human tumor cells (13,15,182). 
Furthermore, RASSF1A can also contain point mutations in up to 15% of primary tumors 
(183). Thus, RASSF1A may be one of the most frequently inactivated tumor suppressors 
identified in human cancer to date (15). 
 The RASSF1A protein regulates a broad range of biological processes that are 
essential for normal growth control. Lacking enzymatic activity (15), RASSF1A seems to 
act as a scaffolding molecule in order to modulate tumor suppressor pathways. RASSF1A 
plays a critical role in microtubule stability by interacting with several micro-tubule 
associated proteins (MAPs), in turn forming a complex with microtubules and regulating 
mitosis and cell cycle progression (15). One of the ways RASSF1A is thought to regulate 
the cell cycle is by inhibiting the accumulation of cyclin D1 and blocking the cell cycle at 
the G1/S phase (184,185). Furthermore, there is some evidence suggesting that 
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RASSF1A mediated stabilization of microtubules may have a role in the regulation of 
autophagy (186). RASSF1A has also clearly been implicated in promoting apoptosis by 
associating with pro-apoptotic kinases MST1/2 to modulate their kinase activity, in turn 
activating the HIPPO pathway and inducing cell death (178). More recently, it has been 
shown that RASSF1A is also directly involved in DNA repair by regulating the 
acetylation of the DNA repair protein XPA (187). This finding shows that, in addition to 
acting as a scaffolding molecule, RASSF1A can also regulate protein function by 
modulating their post-translational modifications. However, this function has been 
defined solely for RASSF1A, the best characterized member of the family, and it remains 
to be seen if the other members of the RASSF family can perform such a powerful 
function. While the functions of the majority of the other RASSF family members remain 
unclear, more evidence has come to light suggesting that another RASSF member may be 
just as potent a tumor suppressor: RASSF5, or NORE1A. 
 
1.3.2 – The Tumor Suppressor NORE1A (RASSF5): 
 
 NORE1 was the first member of the RASSF family of proteins to be cloned (14). 
While differential promoter usage and alternative splicing mechanisms leads to the 
expression of three transcripts (A-C), NORE1A is the longest and most common isoform. 
NORE1A has been shown to have approximately 50% sequence homology to the 
relatively well characterized RASSF1A tumor suppressor (188). As in the case with 
RASSF1A, the initial evidence suggested that NORE1A behaves as a tumor suppressor. 
NORE1A is frequently down-regulated in human tumors by promoter methylation, and in 
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some primary tumors the NORE1A locus undergoes loss of heterozygosity (15,189). In 
addition, a genetic translocation event leading to loss of NORE1A results in a familial 
human cancer syndrome (18). Several in vitro studies have shown that exogenous 
expression of NORE1A can promote apoptosis and in some cases cell cycle arrest 
(12,17,19). Additionally, restoring endogenous levels of NORE1A expression to a 
NORE1A-negative tumor cell line suppressed the tumorigenic phenotype (12). While the 
evidence clearly implicates NORE1A as a tumor suppressor, how NORE1A functions in 
this role remains relatively unclear. 
Interestingly, NORE1A has been shown to associate with oncogenic Ras via its 
RA domain in a GTP-dependent manner (19), with a similar affinity compared to that of 
other known Ras effectors (190). Because NORE1A was shown to form an endogenous 
complex with Ras in cells (19), NORE1A is now considered a bona fide Ras effector 
(191). Since activated forms of Ras are known to paradoxically induce growth inhibitory 
pathways in addition to classical growth promoting ones, it was thought that NORE1A 
could behave as a critical negative effector of Ras. 
One of the first mechanisms of NORE1A mediated tumor suppression 
investigated was the ability of NORE1A to bind to the kinases MST1/2, key components 
that feed into the HIPPO tumor suppressor pathway (192). Briefly, the core of the HIPPO 
pathway consists of a kinase cascade, whereby MST1/2 phosphorylate and activate the 
kinases LATS1/2, in turn phosphorylating the transcriptional co-activators YAP and TAZ 
(193). Phosphorylation of YAP and TAZ will either retain them in the cytoplasm or 
promote their degradation, in turn promoting the induction of apoptosis (193). Initial 
work published by Avruch and colleagues suggested that Ras/NORE1A can drive 
34 
 
apoptosis by binding to MST1/2 (192). However, their findings failed to show an 
increase in the kinase activity of MST1/2 as well as not showing any effects on 
YAP/TAZ phosphorylation. Interestingly, a report by Aoyama et al. showed that mutants 
of NORE1A lacking the MST-binding domain can inhibit tumor cell growth 
independently of the MST1/2 kinases (17). Thus, the role of NORE1A in regulating the 
HIPPO pathway is quite controversial, though it seems that by some currently unknown 
mechanism NORE1A may modulate effectors of the HIPPO pathway, either directly via 
MST1/2 or non-canonically. 
Recently, work performed by Schmidt and colleagues has characterized a novel 
Ras-NORE1A axis in the regulation of the Wnt pathway. They showed that NORE1A 
forms a direct, endogenous, Ras-regulated complex with the E3 ubiquitin ligase β-TrCP, 
ultimately promoting the degradation of the terminal executor of Wnt signaling, β-catenin 
(194). β-catenin serves as both a nuclear transcriptional regulator and a key component of 
adherens junctions (195). Thus, by recruiting β-TrCP and promoting the ubiquitination 
and subsequent degradation of β-catenin, NORE1A can regulate the stability and turnover 
of important proteins. Furthermore, the work identifies a novel Ras regulated pathway of 
growth inhibition. However, Ras is known to negatively affect growth not only by 
regulating apoptotic pathways, but also by promoting senescence. Once it was established 
that NORE1A seemed to play a role in cell cycle arrest (191), it raised the intriguing 






1.3.3 – The Link Between Ras-Induced Senescence and NORE1A: 
 
 It is widely believed that the senescence response is a crucial fail-safe mechanism 
that protects the cells from tumorigenic transformation, such as aberrant Ras signaling 
(196). Ras-induced senescence came to light in 1997, when it was shown to promote G1 
arrest and cause an increase in the senescent proteins p53, p21, and p16 (159). While the 
mechanisms are not fully defined, it is widely accepted that Ras-induced senescence 
primarily involves the p53 and Rb pathways (169). The link between Ras and the 
activation of these two powerful senescence pathways is still missing, though the 
hypothesis remains that it must be regulating these pathways through one of its negative 
effectors. 
 NORE1A promotes apoptosis when over-expressed or in the presence of activated 
Ras, but lower, more physiological levels of NORE1A seem to promote G1 cell cycle 
arrest (17). With the exception of the MST kinases, the signaling pathways involved in 
NORE1A mediated tumor suppression remain poorly defined. In order to try and identify 
novel mechanisms of action of NORE1A, Calvisi and colleagues performed a microarray 
analysis of kidney cells induced to express NORE1A at physiological levels, and 
determine alterations in gene expression by qRT-PCR. Of particular interest was the 
induction of the cyclin-dependent kinase (cdk) inhibitor p21
CIP1
 (191). Similar to 
NORE1A, over-expression of p21
CIP1
 induces G1 arrest (197). The study showed that 
NORE1A over-expression up-regulates p21
CIP1
, but more importantly, loss of NORE1A 
expression led to the reduction in p21
CIP1
 levels (191). One of the best characterized 
activators of p21
CIP1
 is p53 (198). Interestingly, the work done by Calvisi et al. showed 
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that the activation of p21
CIP1
 by NORE1A is p53 dependent, and that by some unknown 
mechanism, NORE1A promoted the nuclear translocation of p53 (191). This links 
NORE1A to the p21
CIP1
/p53 pathway, suggesting that NORE1A might be involved in 
Ras mediated activation of p53. 
 As Ras senescence pathways are known to operate, in part, via p53 (159), 
Donninger et al. examined the potential role of NORE1A in Ras-induced senescence and 
p53 activation. Their findings showed that NORE1A is a potent inducer of p53 dependent 
senescence, and that knockdown of NORE1A impaired Ras-induced senescence and 
enhanced its transforming ability (20). Specifically, NORE1A forms an endogenous, Ras 
regulated complex with the kinase HIPK2, and that this interaction is essential for 
Ras/NORE1A induced senescence (20). Collectively, they showed that NORE1A 
positively regulates the pro-senescent post-translational modifications of p53 while also 
negatively regulating its pro-apoptotic modifications, which occur as a result of Ras 
mediated scaffolding of p53 and HIPK2 via NORE1A. While this work clearly implicates 
NORE1A as a senescence effector of Ras by activating p53, the loss of p53 did not 
completely abrogate the ability of NORE1A to induce senescence, suggesting that there 
might be additional mechanisms by which NORE1A can promote senescence. In addition 
to the p53 pathway, Ras can promote the induction of senescence by activating another 
tumor suppressor: the retinoblastoma protein, Rb. 
 
1.4 – The Retinoblastoma Tumor Suppressor: 
 The retinoblastoma susceptibility gene (Rb-1) was the first tumor suppressor to be 
cloned, and was originally identified in pediatric malignant tumors of the retina known as 
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retinoblastoma (199). Rb has now been identified as a crucial tumor suppressor and is 
believed to be directly or indirectly inactivated in nearly all human cancers (21). The 
Retinoblastoma tumor suppressor belongs to a cellular pathway that plays a crucial role 
in restricting the G1-S transition of the cell cycle (200). However, it is now evident that 
Rb plays multiple tumor suppressive functions in addition to its proto-typical role of cell 
cycle regulation. Interestingly, Rb has been shown to bind to over one hundred protein 
partners and has been shown to mediate transcriptional regulation of hundreds of target 
genes. These protein partners and transcriptional targets are thought to mediate the 
numerous cellular functions of Rb, including temporary and permanent cell cycle arrest, 
genomic stability, and differentiation (21). For a long time, Rb has been viewed as “just” 
a regulator of cell cycle progression; however, recent observations indicate that Rb 
functions in multiple pathways and biological processes that are dysregulated during 
tumor initiation and progression (200). 
 
1.4.1 – The Discovery of Rb: 
 
 Retinoblastoma (Rb) is the most common intra-ocular malignant tumor in 
childhood, with an incidence of 1 in 15,000 live births (201). The most important studies 
to investigate the pathogenesis of retinoblastoma began with work published by Knudson 
in 1971, which concluded that retinoblastoma could be inherited and formulated the 
“two-hit theory” in order to explain its pathogenesis (202). He believed that the tumor 
phenotype is not apparent unless both copies of the gene are damaged. The cloning of the 
Rb gene and the identification of biallelic Rb mutations in retinoblastoma tumors confirm 
38 
 
the hypothesis that such gene products exert the action of a tumor suppressor. Several 
human tumors show mutations and deletions of the Rb gene, and inherited allelic loss of 
Rb confers increased susceptibility to cancer formation (203). 
 
1.4.2 – Rb and Cancer: 
 
 Mutations in the Rb pathway are almost universal in cancer, but different 
components of this pathway are selectively affected in distinct cancer types (200). 
Originally, it was shown that the Rb-1 gene is a frequent target for direct mutation only in 
small cell lung carcinoma and retinoblastoma (204,205). However, multiple reports have 
gone on to show that mutations affecting the retinoblastoma gene are actually frequently 
encountered in other cancers, including osteosarcoma, prostate, and breast cancer (206). 
As a further indication of its fundamental role in tumor suppression, Rb can be 
functionally inactivated by constitutive hyperphosphorylation in tumors that do not have 
mutations in the retinoblastoma gene (207). Furthermore, loss of heterozygosity at the 
Rb-1 locus has been reported in many different sporadic cancers, suggesting that it is 
directly mutated outside of the lung and retina, but on a less frequent basis (208). Lastly, 
DNA tumor viruses that express oncoproteins, such as adenovirus E1A, SV40 large 
tumor antigen, and human papillomavirus (HPV) E7, bind and inactivate Rb (209-211). 
These proteins have all been shown to be required in order for the viruses to transform 
cells. However, the retinoblastoma protein is most frequently inactivated in human cancer 
by the negative regulatory activity of cyclin dependent kinases (212). Collectively, it is 
the dysfunction of the Rb pathway that is considered to be critical for the development 
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for the majority of human cancers, in large part because of the loss of functional tumor 
suppressive functions of Rb. 
 
1.4.3 – Tumor Suppressive Functions of Rb: 
 
 Since the late 1980s, it has been shown that Rb behaves as a tumor suppressor. 
Over the years, the mechanisms by which Rb can promote its tumor suppressive 
functions have been elucidated. It is now believed that the presence of Rb may prevent 
tumor formation by inducing differentiation, controlling-cell cycle arrest, maintaining 
genomic stability, and inducing senescence in response to oncogenic stresses (21). 
Furthermore, the absence of Rb has been associated with increased angiogenesis (213) 
and metastasis (214), although the mediators of these functions are less well understood. 
While copious amounts of research has been done to characterize the mechanisms of 
actions of Rb, the fundamental aspects of Rb mediated tumor suppression focus on two 
critical components: regulation of the cell cycle and induction of cellular senescence. 
 
1.4.3.1 – Rb and Cell Cycle Progression: 
 
 Two of the most important proteins involved in the cell cycle machinery are 
cyclin-dependent kinases (Cdks) and cyclins. Cyclin/Cdk complexes are formed during 
distinct phases of the cell cycle, and are specifically involved in the phosphorylation of a 
distinct set of target proteins, including Rb. The fluctuation in cyclin expression and the 
resultant oscillation in Cdk activity forms the basis of a coordinated cell cycle 
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progression. Cdks activated in response to mitogenic stimuli phosphorylate and inactivate 
Rb, allowing for progression through the cell-cycle (215). 
 One of the critical steps in cell cycle progression is the G1 to S transition phase. 
At this particular point, the cell may decide whether to continue its advance and complete 
the cell cycle. This point is referred to as the “restriction point,” or the R point, and is 
thought to be a critical event in normal cellular proliferation control (216). It is perceived 
that Rb is the key mediator that serves as the R point switch. Rb is hypophosphorylated in 
resting G0 cells, is increasingly phosphorylated during progression through G1 and is 
maintained in a hyperphosphorylated state until late mitosis (217-219). 
 When in its actively growth-suppressing hypophosphorylated state, Rb physically 
associates with E2F factors and blocks their ability to activate expression of genes that 
encode products necessary for S-phase progression (Figure 5). The Rb proteins repress 
gene transcription required for transition from G1 to S phase by directly binding to the 
trans-activation domain of E2F and by binding to the promoter of these genes as a 
complex with E2F (220). The importance of the Rb-E2F interaction in cell growth control 
is demonstrated by the finding that all naturally occurring Rb mutants isolated from 
human tumors lack the ability to bind and negatively regulate E2F (221). However, Rb 
can regulate G1-S transition through E2F independent mechanisms. Rb has been shown 
to inhibit Cdk activity and G1-S progression by increasing the expression of p27; 
furthermore,  Rb can stabilize the p27 protein by binding the Skp2 protein and interfering 
with the Skp2-p27 complex, thus avoiding p27 ubiquitination (222).   
 In addition to directly binding and blocking the activation of E2F transcription 








Figure 5: A model for cell cycle regulation by Rb. The Rb tumor suppressor is 
primarily regulated by its phosphorylation status. When Rb is hypophosphorylated, it will 
bind to and inhibit the activity of E2F transcription factors, as well as recruit chromatin 
modifying enzymes to repress the transcription of E2F responsive genes. However, 
cyclin/Cdk complexes can be activated in response to mitogenic stimuli and can 
phosphorylate and inactivate Rb, allowing for progression through the cell cycle. While 
the mechanisms involved in Rb phosphorylation are well characterized, the activation of 
Rb by dephosphorylation remains poorly defined. 
  
Copyright permissions not required for this type of use. 
    Figure generated by MacDonald, JI and Dick, FA. 
Reprinted with permission of Creative Commons Copyright Licensing. 
          <http://creativecommons.org/licenses/by/3.0/>  
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interaction with proteins such as hBRM, BRG1, HDAC1, and SUV39H1 (223) which are 
involved in nucleosome remodeling, histone acetylation/deacetylation, and methylation, 
respectively. Of particular interest is the ability of Rb to recruit HDAC1 to E2F 
complexes to repress gene expression, such as cyclin E (224). Work done by Zhang et al 
in 2000 showed that histone deacetylase is involved in modulating the repressive activity 
of Rb on E2F gene promoters (225). In conclusion, Rb has now been shown to have 
multiple mechanisms involving the regulation of cell cycle. Interestingly, prolonged cell-
cycle arrest can lead to the induction of senescence. 
 
1.4.3.2 – Rb and Senescence: 
 
 Multiple reports have shown that Rb is required for oncogene induced senescence 
in mouse cells (226,227), and it is widely believed that Rb can induce the senescence 
phenotype in part by promoting a permanent cell cycle arrest. However, in human cells 
both the p53 and the Rb pathways have to be inactivated in order for Ras to bypass 
senescence (159), suggesting that both pathways are required in human systems. These 
differences in the senescence mechanism may provide a logical explanation as to why it 
is easier to transform rodent cells than human cells in experimental systems (228). While 
it is clear that Rb is required for Ras-induced senescence, the mechanisms linking Ras to 
the Rb pathway remain unknown. 
One mechanism by which Rb can promote this irreversible cell cycle arrest is by 
promoting the formation of heterochromatin around genes required for cell proliferation, 
such as E2F target genes. Such heterochromatin structures are referred to as SAHF 
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(senescence-associated heterochromatin foci). While these structures are critical for the 
induction of senescence, it does not explain how Rb is activated to promote such a 
phenotype. In addition, work performed by Chicas and colleagues showed that, in 
addition to E2F repression, Rb can repress the replication machinery of senescent cells in 
part by repressing the expression of cyclin E1 (215).   
 During Ras-induced senescence, Rb can be activated by the cyclin-dependent 
kinase inhibitors (CKIs) which block the Cdks that normally inactivate the Rb protein by 
phosphorylation (229). Two of the most important CKIs are p21 and p16, both of which 
are simultaneously required for Ras-induced senescence in human cells (230). 
Interestingly, inhibition of Cdks is not the only means to inhibit Rb phosphorylation. 
While the mechanisms that lead to the phosphorylation of Rb are well documented, the 
knowledge of the process that counteracts Rb phosphorylation is still quite limited (231). 
Recent work has now shown that two phosphatases, PP1 and PP2, play pleotropoic roles 
in the mammalian cell cycle, particularly in mitosis. Further support for a major role for 
PP1 in Rb dephosphorylation came from a yeast two-hybrid screen that reported a direct 
association between Rb and the catalytic subunit of PP1. It was later shown through in 
vitro binding assays that isoform PP1A preferentially binds the hypophosphorylated form 
of Rb and that this association occurs in early G1. It must be noted that subsequent work 
showed that Rb actually binds all PP1 isoforms, but that PP1A is widely considered to be 
one of the major cellular phosphatases involved in Rb dephosphorylation (232-236). 
Interestingly, it has been recently reported that PP1A enzymatic activity is regulated by 
Ras (237) and additional reports have shown a correlation between Ras activation and 
PP1/PP2A activation (238). More importantly, work performed by Castro and colleagues 
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showed that PP1A could behave as a tumor suppressor in human cells through its 
contribution to Ras-induced senescence (22). This highlights the importance of Rb 
activation by dephosphorylation in order to promote Ras-induced senescence. However, 
the mechanism by which Ras regulates PP1A remains unknown. 
 
1.5 – A Novel Signaling Pathway for NORE1A Induced Senescence: 
 
 Increasing evidence has implicated Ras-induced senescence as a potent barrier 
against malignant transformation, and it is widely believed that loss of functional 
senescence pathways allows Ras to bypass senescence induction and drive 
transformation. The exact mechanisms by which Ras induces senescence are not fully 
understood, but center around two powerful senescence effectors: p53 and Rb. Ras has 
been shown to promote senescence by activating both of these tumor suppressors. And 
while p53 and Rb are required to promote Ras-induced senescence, the mechanisms 
linking Ras to p53 and Rb remain unknown. 
 Recently, NORE1A has been identified as a bona fide tumor suppressor, and has 
now been shown to be a negative effector of Ras. While initial findings depicted a novel 
role for NORE1A as a mediator of Ras-induced apoptosis, the work revolved around 
artificial, over-expression studies, and thus may have masked the true tumor suppressive 
functions of NORE1A. In 2009, work performed using more physiological levels of 
NORE1A expression strongly suggested that NORE1A may be far more important in cell 
cycle arrest, bringing up the intriguing possibility that NORE1A might be playing a role 
in oncogene induced senescence. Recent work has now clearly implicated NORE1A as a 
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direct, potent senescence effector of Ras. These groundbreaking findings by Donninger et 
al. highlight that NORE1A promotes Ras-induced senescence by scaffolding HIPK2 to 
p53 in a Ras dependent manner, in turn modulating the pro-senescent post-translational 
modifications of p53. Although NORE1A acts through p53 to promote senescence, some 
of the pro-senescent phenotype of NORE1A still remains even after all p53 has been 
removed. This suggests that NORE1A induced senescence may not be promoted 
exclusively by p53, pointing to the possibility that NORE1A may have additional, 
previously unidentified mechanisms to activate Ras-induced senescence. Bearing in mind 
that the onset of senescence in human cells requires both p53 and Rb, we hypothesized 
that NORE1A might also act through the Rb pathway. Furthermore, PP1A was detected 
in complex with NORE1A in a yeast two-hybrid screen (23), suggesting that these two 
proteins may interact and potentially provide the missing link that allows Ras to regulate 
Rb in order to promote senescence. 
 Work presented in this dissertation demonstrates a novel mechanism, in addition 
to p53, by which NORE1A can promote senescence induction. We will show evidence 
that NORE1A can activate the powerful Rb tumor suppressor. Through the formation of 
an endogenous, Ras regulated complex with the phosphatase PP1A, NORE1A can 
scaffold PP1A onto Rb in turn promoting its dephosphorylation, a pro-senescent event. 
Additionally, we show that NORE1A requires Rb to promote senescence in mouse 
embryonic fibroblasts, and that loss of Rb significantly suppresses NORE1A induced 
senescence in human cells. These findings explain why NORE1A is such a powerful 
tumor suppressor. Collectively, NORE1A seems to behave as a critical senescence 
effector of Ras, by linking Ras to both the p53 and Rb pathways to fully promote the 
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senescent phenotype. In addition to regulating Rb dephosphorylation, we also provide 
evidence that NORE1A can regulate some of the non-phosphorylation post-translational 
modifications of Rb, including the acetylation and the SUMOylation, both of which are 












MATERIALS AND METHODS 
 
2.1 – Vectors and Plasmids: 
 
pCDNA3-HA and pCDNA3-FLAG – pCDNA3 expression plasmid vector was purchased 
from Invitrogen (Carlsbad, CA). It contains a CMV promoter upstream of a multiple 
cloning site; however, it does not express an epitope tag, making it inconvenient for basic 
biological studies. Therefore, we generated pCDNA3 expression vectors containing fused 
HA and FLAG epitope tags, which were performed by Dr. Geoffrey Clark. Ultimately, 
the expression of inserted genes results in either a fused HA of FLAG tag on the N-
terminus of the protein. 
 
pEGFP-C1 – This vector construct was purchased from Clontech (Mountain View, CA). 
It is driven by a CMV promoter and allows for a Green Fluorescent Protein (GFP) tag to 
be fused to cDNAs that can be inserted into the multiple cloning site. This is a very useful 
tool that can be used to track protein localization within the cell by fluorescent 
microscopy as well as for protein-protein interactions via coimmunoprecipitations 
(described in Section 2.8.1). 
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pmKATE2-C – This vector construct was obtained from Evrogen (Moscow, Russia). 
Nearly identical to pEGFP-C1, this construct expresses a Red Fluorescent Protein (RFP) 
tag that can be fused to cDNAs inserted into the multiple cloning site, an can be used in a 
similar manner for biological assays. 
 
NORE1A – NORE1A is the centerpiece of this dissertation project. The full length human 
NORE1A was purchased from Origene (Rockville, MD) and was sub-cloned into the 
relevant expression constructs by Dr. M. Lee Schmidt. Briefly, the NORE1A cDNA 
clone was PCR amplified with primers “hNore1a5” with the sequence 5’ – 
GCAGATCTATGGCCATG GCGTCCCCGGCCATC – 3’ and “hNore1a3’” with the 
sequence 5’ – GCGAATTCTTACCCA GGTTTGCCCTGGGATTC – 3’ to yield a 1273 
base pair DNA fragment with 5’-BglII and 3’-EcoRI restriction sites. The fragment was 
TOPO cloned into pCR2.1-TOPO for sequencing and sub-cloning applications. Post-
analytical confirmation, the pCR2.1-TOPO-NORE1A plasmid was digested with BglII 
and EcoRI and ligated into a BamHI/EcoRI digest of a pCDNA3 mammalian expression 
construct containing an in-frame 5’-HA tag and a pCDNA3 construct containing an in-
frame 5’-Flag epitope tag. The BglII/EcoRI digested NORE1A fragment was also ligated 
into both GFP (pEGFP-C1) and KATE (pmKATE2-C) digested with BglII and EcoRI. 
 
H-Ras-12V and K-Ras-12V – pCGN-HA-H-Ras12v was created by cloning the full-
length H-Ras12v cDNA as a BamHI fragment into pCGN vector under the control of a 
CMV promoter (239). KATE-tagged H- and K-Ras12V were generated by subcloning a 
BamHI fragment from pCGN-H- and K-Ras12V into pmKATE2-C. 
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shNORE1A – shRNAs for human NORE1A (#1: 5′-TATATATAGCTATATGCCT-3′; 
#2: 5′-AGCTTTGTGCTAAAGGAGA-3′; Scrambled: 5′ATCTCGCTTGGGCGAGAGT 
AAG-3′; RHS4531-EG83593) were obtained from Open Biosystems (Rockford, IL) (20). 
 
shRb – pLKO-Rb1-shRNA-19 and 63 were purchased from Addgene (Plasmid #25640 
and 25641). Briefly, unique short hairpin RNAs (shRNA) to the RB1 mRNA in the 
pLKO.1-Puro lentiviral expression vector were obtained from Open Biosystems. Clones 
19 and 63 were originally shown to have >99% knockdown of Rb expression relative to 
the empty pLKO.1-infected clone (240). 
 
siPP1A – Control (sc-37007) and siPP1A siRNA (sc-36299) were purchased from Santa 
Cruz Biotechnology (Santa Cruz, CA). While the sequences for the siPP1A siRNA 
constructs were not disclosed by Santa Cruz, it is noted that this PP1A siRNA is a pool of 
three target-specific 19-25 nucleotide siRNAs designed to knock down the gene 
expression of human PP1A. 
 
Rb – Human Rb expression construct (pGS5L-HA-Rb) was obtained from Addgene 
(Plasmid #10720) and digested with BamHI/NheI and NheI/EcoRI in two separate 
digests to generate 1.9 Kb and 0.8 Kb fragments, respectively. The two fragments were 
cloned into pEGFP-C1 (Clontech) digested with BglII/EcoR1 to generate a GFP-tagged 
full length Rb expression construct. To maintain consistency of plasmid backbones, an 
identical double digest was performed in order to generate a pcDNA3.1-HA-Rb 
construct. Briefly, following a double digest of pGS5L-HA-Rb to generate the 1.9 Kb and 
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0.8 Kb fragments, we set up a ligation using both fragments along with a pcDNA3.1-HA 
fragment from HA-XpA-2KQ that had been digested BamHI/EcoRI.  
 
Ubiquitin – We obtained the full length, wild-type HA-tagged Ubiquitin expression 
construct, pRK5-HA-Ubiquitin-WT, from Addgene (Plasmid #17608). 
 
PP1A – We purchased the full length, wild-type GFP-tagged PP1A expression construct, 
pEGFP(C1)-PP1A, from Addgene (Plasmid #44224). 
 
SUMO1 – We purchased the full length, wild-type HA-tagged SUMO1 expression 
construct, pcDNA3-HA-SUMO1-WT, from Addgene (Plasmid #48966). 
 
PCAF – We obtained the full length, wild-type FLAG-tagged PCAF expression 
construct, pCI-FLAG-PCAF, from Addgene (Plasmid #8941). 
 
Pc2 – pEGFP-Pc2 (wild-type) was generously provided by Dr. Andrew Sharrocks, from 
the University of Manchester (Manchester, United Kingdom). 
 
IL-6-PROM-01-Luc – A luciferase reporter construct containing an IL-6 promoter was 






2.2 – Antibodies: 
 
Anti-GFP – The primary antibody detecting the GFP-epitope tag was purchased from 
Santa Cruz Biotechnology (sc-9996). For western blot analysis and the detection of 
proteins containing a GFP tag, the GFP-antibody was diluted at 1:500 in a 5% milk 
solution of 1X TBST (TBS-Tween: 50mM Tris-HCl, pH 7.4, 150mM NaCl, 0.1% 
Tween-20). The blots were incubated in antibody solution at 4°C overnight. After 
incubation with primary antibody, blots were exposed to a mouse-IgG-HRP secondary 
(Cat. # NA931-1ML) purchased from Amersham (acquired by GE Healthcare, Uppsala 
U.K.) at a dilution of 1:10,000 in 1X TBST for 1 hour at room temperature, followed by 
detection by West Pico Enhanced Chemi-Luminescence purchased from Thermo Fisher 
Scientific (Rockford, IL). 
 
Anti-HA – The primary antibody detecting the HA-epitope tag (Cat# MMS-101P) was 
purchased from Covance Inc. (Princeton, NJ). For detection of HA-tagged proteins on a 
western blot, the antibody was generally diluted at 1:10,000 in a 5% milk solution of 1X 
TBST. However, for particular instances such as detections of weaker protein-protein 
interactions, the HA primary antibody was used at a dilution of 1:5,000. Blots were 
incubated in primary antibody solutions overnight at 4°C. Following the primary 
antibody incubation, western blots were exposed to a mouse-IgG-HRP secondary at a 
dilution of 1:10,000 in 1X TBST for 1 hour at room temperature, and ultimately detected 




Anti-FLAG – The primary antibody used for detection of proteins with FLAG epitope 
tags was purchase from Sigma (Cat# F1804). The antibody was diluted at 1:1,000 in a 
5% milk solution of 1X TBST solution, and blots were incubated overnight at 4°C. After 
the incubation with primary antibody, blots were exposed to a mouse-IgG-HRP 
secondary antibody at a dilution of 1:10,000 in 1X TBST for 1 hour at room temperature 
and detected by West Pico ECL. 
 
Anti-tRFP – The primary antibody used for detecting the KATE epitope tag was 
purchased from Evrogen (Cat#AB233). While this primary antibody is generated to 
detect the RFP tag, it is also able to detect the mKate2 tag, allowing it to be effective for 
our studies. Western blots were incubated in the anti-RFP antibody at a dilution of 
1:1,000 in a 5% BSA (bovine serum albumin) (Sigma Cat. #A3059-100G) solution in 1X 
TBST solution at 4°C overnight. Following incubation in primary antibody, blots were 
exposed to a Goat anti-Rabbit-HRP secondary antibody from KPL Inc. (Gaithersburg, 
MD) (Cat. #374-1506) at a dilution of 1:10,000 in 1X TBST for 1 hour at room 
temperature, and detected using West Pico ECL. 
 
Anti-NORE1A - Rabbit polyclonal NORE1A antibodies were raised against the synthetic 
human NORE1A peptide: KYDKFRQKLEEALRESQGKPG by ProSci (Poway, CA). 
Two different rabbit polyclonal antibodies were generated by ProSci: PAS #17071 
(0.73mg/mLx2.75mL=2.0mg) and PAS #17072 (1.17mg/mLx2.0mL=2.34mg), both in 
PBS with 0.02% NaN3. The date of generation was October 3
rd
, 2014. These antibodies 
were used for detection of NORE1A on western blots and also for immunoprecipitations 
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(IP). After performing test IPs using over-expression studies, we concluded that PAS 
#17071 was better suited for IPs, and PAS #17072 would be used for western blot 
analysis. For IPs, whole cell lysates were incubated with 10 µL (equaling approximately 
7.3 µg) of PAS #17071 antibody in 1 mL final volume of modified RIPA buffer 
overnight, following by a 4 hour immunoprecipitation using rabbit conjugated agarose 
beads purchased from eBiosciences Inc. (acquired by Rockland Inc., Pottstown PA) (Cat. 
#00-8800-25). For full IP protocol, see Section 2.8.1.2) – immunoprecipitations. For 
western blot analysis, the PAS #17072 antibody was added to a 5% milk in 1XTBST 
solution at a dilution of 1:500 and incubated at 4°C overnight. The blots were then 
probed with a Rabbit-IgG-HRP (KPL) secondary antibody at a dilution of 1:10,000 in 1X 
TBST for 1 hour at room temperature, followed by detection using a West Pico ECL. 
 
Anti-Phospho-Rb-Ser795 – When western blotting for phosphorylated levels of 
endogenous Rb protein, an anti-Rb antibody that specifically recognized phosphorylated 
Rb at Serine 795 was purchase from Cell Signaling Technology (Beverly, MA) (Cat. 
#9301). This antibody was diluted at 1:1,000 in a 5% BSA/1XTBST solution and blots 
were incubated overnight at 4°C. Following incubation in primary antibody, blots were 
exposed to a goat anti-Rabbit-HRP secondary antibody at a dilution of 1:10,000 in 
1XTBST solution for 1 hour at room temperature, followed by detection of protein using 
West Pico ECL. 
 
Anti-Rb [4H1] – Endogenous levels of total Rb protein was detected on a western blot 
using an antibody purchased from Cell Signaling (Cat. #9309) diluted at a concentration 
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of 1:1,000 in 5% milk in 1X TBST. Blots were incubated in primary antibody at 4°C 
overnight. Following the primary antibody incubation, blots were probed with a mouse-
IgG-HRP secondary antibody diluted at 1:10,000 in 1X TBST solution for 1 hour at room 
temperature, followed by detection using West Pico ECL. 
 
Anti-PP1A – When western blotting for endogenous levels of PP1A protein, an anti-
PP1A antibody (C-19) purchased from Santa Cruz (sc-6104), and is a goat polyclonal 
IgG provided at 200 µg/mL, and its epitope maps at the C-terminus of PP1A of human 
origin. This antibody was diluted at 1:200 in a 5% milk in 1X TBST solution; blots were 
incubated in PP1A primary antibody overnight at 4°C. Following the overnight 
incubation, blots were probed with a rabbit anti-Goat IgG-HRP (purchased from Santa 
Cruz, sc-2768) diluted at 1:10,000 in 5% milk in 1X TBST solution for 1 hour at room 
temperatures, followed by protein detection using West Pico ECL. 
 
Mouse and Rabbit-HRP TrueBlot Secondary Antibody – Instances occurred when 
experiments required agarose conjugated beads that are bound with mouse or rabbit 
secondary antibodies. This can cause the heavy and light chains of antibodies to be 
detected by the respective mouse/rabbit secondary antibodies during western blot 
analysis. Fortunately, a TrueBlot® product line of secondary antibodies generated by 
Rockland Inc. do not detect heavy and light chain IgG bands. Thus, there were some 
cases were this secondary antibody was used rather than the standard mouse-HRP 
secondary antibody previously mentioned. Western blots were incubated with the 
TrueBlot Mouse antibody (Cat. #18-8817-33) was diluted at a dilution of 1:2,000 in a 5% 
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milk in 1X TBST solution for approximately 1 hour, followed by detection using West 
Pico ECL. Similarly, the TrueBlot Rabbit-HRP secondary antibody does not detect the 
heavy and light chains of antibodies conjugated to agarose beads. When necessary, the 
TrueBlot Rabbit secondary (Cat. #18-8814-33) was used in exactly the same manner as 
the TrueBlot Mouse secondary antibody. 
 
2.3 – Cell Lines: 
 
HEK 293 – Human Embryonic Kidney 293 cells (HEK 293) are a specific cell line 
originally derived from human embryonic kidney cells. These embryonic kidney cells 
were transformed by exposing cells to sheared fragments of adenovirus type 5 DNA 
(241). HEK 293 cells are straightforward to grow in culture, but more importantly 
transfect very readily and have been widely used in cell biology as hosts for gene 
expression. These cells were purchased from ATCC (Manassas, VA) and were widely 
used for our studies. HEK 293 cells are grown in DMEM supplemented with 10% FBS. 
 
HEK 293T – An important variant of the HEK 293 cell line is the HEK-293T cell line, 
which have been modified to express the SV40 Large T-antigen, which allows for 
increased protein production by allowing replication of transfected plasmids containing 
the SV40 origin of replication. This cell line was primarily used for coimmuno-
precipitation experiments. This cell line was also obtained from ATCC and are cultured 




COS-7 – The COS-7 cell line (an abbreviation for CV-1 in Origin with SV40 genes) is a 
fibroblast-like cell line derived from the kidney cells of the African green monkey 
(Cercopithecus aethiops). COS-7 cells were developed by Yakov Gluzman by 
immortalizing CV-1 cells with a mutant version of the SV40 virus that can produce the 
Large-T antigen but has a defect in genomic replication (242). While not being human in 
origin, COS-7 cells are a valuable tool to study potential co-localization of fluorescently 
labeled proteins, as their flat morphology allow the option to do high resolution, live-cell 
imaging microscopy as it reduces background fluorescence. This cell line was purchased 
from ATCC and is maintained in DMEM supplemented with 10% FBS. 
 
A549 – Purchased from ATCC, A549s are human lung adenocarcinoma epithelial cells. 
This cell line was initiated by D.J. Giard and colleagues through explants culture of lung 
carcinomatous tissue from a 58-year old Caucasian male (derivation information courtesy 
of ATCC). This cell line harbors the K-Ras (G12S) mutation, giving these cells a 
constitutively activated Ras protein. In addition, these cells are null for NORE1A 
expression, and it has been recently shown that expressing NORE1A in A549 cells leads 
to the induction of cellular senescence (20). A549s also express wild-type p53 and Rb. 
These cells were cultured in DMEM supplemented with 10% FBS. 
 
NCI-H1299 – This cell line, obtained from ATCC, is a human non-small cell lung 
carcinoma derived from the lymph node. There are two significant reasons why these 
cells are so highly transformed. First, H1299 cells have a point mutation in N-Ras (N-
Ras-Q61K), rendering it constitutively active. Second, they do not express p53 (243) as a 
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result of a homozygous partial deletion within the p53 gene. These cells are cultured in 
RPMI medium supplemented with 10% FBS. 
 
HBEC-3KT – This is an immortalized, non-transformed human bronchial epithelial cell 
line, which was provided courtesy of Jerry Shay (UT South Western, Dallas, TX). This 
cell line was established by infecting primary human bronchial epithelial cell culture with 
human telomerase (hTERT) and mouse cyclin dependent kinase 4 (CDK4) expressing 
retrovirus constructs and selecting with Puromycin and G418 (244). Because they were 
immortalized without the use of any viral oncogenes, such cells can almost be considered 
primary cells. These cells were cultured in keratinocyte serum-free medium containing 
bovine pituitary extract and recombinant epidermal growth factor (Invitrogen). 
 
HepG2 – This is a human hepatocellular carcinoma cell line derived from the liver tissue 
of a 15-year old Caucasian male who had well-differentiated hepatocellular carcinoma, 
which is the fifth most common cancer worldwide. HepG2 cells contain a mutant Ras (N-
Ras-Q61L) but have wild-type p53 and Rb (245). More importantly, NORE1A and PP1A 
protein can be detected in this cell line via western blot analysis, which is the 
predominant reason for which we performed endogenous coimmunoprecipitations in this 
cell line. HepG2 cells are maintained in DMEM supplemented with 10% FBS. 
 
MEFs – Mouse embryonic fibroblasts (MEFs) are primary murine cells with the 
senescence machinery intact that can be isolated from mouse embryos and can be 
expanded in culture. Interestingly, such cells undergo significant induction of senescence 
58 
 
in the presence of activated Ras, making these cells useful tools to study Ras effectors 
and their role in senescence. Wild-type and Rb
-/-
 MEFs were generously provided by Dr. 
Brian Clem (University of Louisville, Louisville, KY) and were used to study the 
potential role of Rb in NORE1A mediated senescence. Rb
-/-
 MEFs were generated and 
validated as previously described (226). MEFs were grown in DMEM supplemented with 
10% FBS. 
 
293FT – The 293FT cell line is a fast-growing, highly transfectable clonal isolate derived 
from human embryonic kidney cells transformed with the SV40 large T antigen. The 
293FT cell line is ideal for generating high-titer lentivirus production. This cell line was 
used to generate lentivirus carrying shRNAs against Rb in order to address the role of Rb 
in NORE1A mediated senescence. A detailed explanation of the generation of lentiviral 
particles is discussed in section 2.7.3. 293FT cells were grown in DMEM supplemented 
with 10% FBS, 1% Pen-Strep, 0.1mM MEM non-essential amino acids, 6mM L-
Glutamine, 1mM MEM sodium pyruvate and 500g/ml G418 sulfate (Corning Cellgro 
Cat. #30-234-CR). 
 
2.4 – Cell Culture Materials: 
 
Growth Media – Different cell lines grow optimally under different conditions, including 
the growth medium. Thus, several specific growth media were obtained. Dulbecco’s 
Modified Eagle’s Medium (DMEM) was purchased from Corning Cellgro (Cat. #10-013-
CV) and is composed of 4.5g/L glucose and supplemented with L-glutamine and 
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pyruvate. The DMEM was further supplemented with 10% FBS (Valley Biomedical) and 
a 1% solution of Penicillin/Streptomycin antibiotic (Corning Cellgro Cat. #30-002-CI). 
RPMI 1640 cell culture medium was purchased from Corning Cellgro (Cat. #10-040-CV) 
with L-glutamine. This medium was further supplemented with 10% FBS (Valley 
Biomedical) and 1% Pen-Strep Antibiotic (Corning Cellgro). HBEC-3KT cells require a 
special growth media formulation and we purchased this medium designed for 
keratinocytes from Invitrogen (Cat. #17005-042). This kit contains Keratinocyte-SFM 
medium (Cat. #10724-011) which was supplemented with provided supplements 25mg 
Bovine Pituitary Extract (BPE) (Cat. #13028-014), 2.5μg human recombinant EGF (Cat# 
10450-013), and 1% Pen-Strep Antibiotic (Corning Cellgro). 
 
Trypsin – Trypsin EDTA (0.25%) was purchased from Corning Cellgro (Cat. #25-053-
CI) and used to remove adherent cells from culture dishes and flasks. Media was 
removed by aspiration from cell culture dishes and washed once with 1X PBS, which was 
purchased from Corning Cellgro (Cat. #21-040-CV and #46-013-CM). The PBS was then 
aspirated and the trypsin-EDTA solution was then added, covering the bottom of the dish 
with a thin layer of solution. The dishes were then placed back into the incubator for 3-5 
minutes allowing the trypsin to remove adherent cells. After the cells were removed from 
the flask, the trypsin-EDTA was neutralized with supplemented culture medium and the 
cells were pelleted by centrifugation (5 minutes at 1500 RPM). The cell pellets were 




Cell Culture Flasks and Dishes – All cells were passaged in either T-25 or T-75 culture 
flasks purchased from TPP. When plating cells for biological experiments, cells were 
plated in 60 mm or 100mm cell culture dishes as well as 6, 12, and 24 well plates, all of 
which were purchased from Greiner Bio-One. In particular instances, 96-well plates were 
purchased from TPP. 
 
Lysis Buffer and Chemicals for Cell Treatment – For biological assays where protein-
protein interactions were not involved, we lysed cells in RIPA buffer purchased from 
Sigma (Cat. #R0278), which contains the following: 150mM NaCl, 1.0%, 1.0% 
IGEPAL® CA630, 0.5% sodium deoxycholate, 0.1% SDS, and 50mM Tris pH 8.0. This 
lysis buffer allows for efficient cell lysis and is suitable for protein detection by western 
blot analysis. To inhibit the proteasome, cells can be treated with a chemical called MG-
132, which we obtained from Sigma (Cat. #C2211-5MG). Stock solutions of MG-132 
were dissolved in DMSO to a concentration of 10 mM and diluted in cell culture media to 
obtain a final working concentration of 10 µM. For the purposes of our studies, cells were 
treated with MG-132 for 6 hours prior to lysis when applicable. To study changes in 
protein stability, we purchased a chemical called cycloheximide from Sigma (Cat. 
#P8833-10MG). It works by inactivating the transferase II enzyme involved in peptide 
chain elongation, ultimately inhibiting protein synthesis. One can then analyze protein 
decay over a time course to determine the stability of a protein of interest. Stock powder 
of cycloheximide was dissolved in 100% ethanol (EtOH) to a concentration of 20 




2.5 – Transfections: 
 
Transfection of DNA plasmids and siRNAs into mammalian cells is a critical 
means by which to study gene function. There are multiple options that are commercially 
available to transfect cells; however, different cell lines can be transfected more or less 
optimally depending on the transfection reagent. Therefore, we used several different 
reagents in order to transfect cells as efficiently as possible. These include: JetPRIME, 
Lipofectamine 3000, and DharmaFECT. 
 
2.5.1 - JetPRIME™ Transfection: 
 
 The JetPRIME™ DNA transfection reagent (VWR Cat# 89137-972) can be 
purchased from Polyplus-Transfection Inc. (Illkirch, France). It is generally described as 
a cationic polymer-based reagent to ensure high DNA transfection efficiency by forming 
positively charged complexes with DNA that can enter the cell via endocytosis, in turn 
releasing plasmid DNA into the cytoplasm, eventually reaching the nucleus. For most of 
our transfection procedures, 1-2 µg of DNA plasmids of choice were mixed in 200 µL of 
JetPRIME™ transfection buffer provided by the manufacturer. To this mix, 2-4 µL of 
JetPRIME™ was added, depending on the amount of DNA (JetPRIME™ was 
consistently added at a ratio of 2 µL per 1µg DNA plasmid). The mix would be vortexed 
for 10 seconds and spun down for 10 seconds using a tale-top micro-centrifuge. The 
DNA/JetPRIME™ mixture was incubated for 10 minutes at room temperature and was 
added dropwise to the dish (in this case, 60 mm dish) and incubated for 6 to 8 hours. 
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After this incubation, the culture media/transfection mix you be aspirated and fresh media 
would be added and remain overnight. This general transfection protocol can be modified 
based on the size of the cell culture dish used as well as the overall amount of DNA 
plasmid desired. This transfection reagent was used for transfections of HEK 293, HEK-
293T and COS-7 cells, and would generally yield high transfection efficiency. However, 
this reagent was not as efficient for transfecting other cells used in this project, such as 
A549 cells. 
 
2.5.2 – Lipofectamine 3000®: 
 
 The Lipofectamine 3000® reagent was purchased from Invitrogen (Cat. 
#LC3000015). It is a lipid based formulation designed for cells that are difficult to 
transfect when using other transfection reagents such as JetPRIME™. For the purposes of 
this project, MEFs and A549 cells were transfected using Lipofectamine 3000® 
according to the manufacturer’s instructions. Cells were plated in 35mm dishes or 12-
well plates (in duplicate) and thus were transfected in a similar manner. First, two tubes, 
(name?) each containing 100 µL of Opti-MEM (Invitrogen Cat. #31985062), were 
prepared. In the first tube, 3.75 µl per µg of DNA was added. In the second tube, the 
respective DNA was added, followed by the addition of 2 µL of P3000™ reagent per 1 
µg of DNA. After mixing both tubes thoroughly, the DNA/P3000™/Opti-MEM mixture 
from tube 2 was added to tube 1 (containing Lipofectamine 3000®/Opti-MEM), further 
mixed and incubated for 5 minutes at room temperature. After the incubation, the mixture 
was added drop-wise to the cells and was incubated for 24 hours. Fresh media would be 
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added to the cells the following day and were incubated for an additional 24-48 hours 
depending on the biological assay being performed.  
 
2.5.3 - DharmaFECT™ siRNA Transfection: 
 
 Transfection of siRNA into cultured mammalian cells required very specific 
transfection reagents. We purchased the DharmaFECT™ transfection reagent from GE 
Healthcare. All siRNA transfections of siPP1A into A549 cells were performed using this 
reagent, and were always performed the day prior to transfections of DNA plasmids. 
First, A549 cells were plated in 35mm dishes at a concentration of 200,000 cells per dish. 
The next day, the siRNA transfection was performed according to the manufacturer’s 
protocol. In tube 1, we diluted the siRNA by adding 5 µL of a 10 mM stock siRNA into 
195 µL of Opti-MEM. In tube 2, we added 5 µL of DharmaFECT reagent (formulation 
#2) into 195 µL of Opti-MEM. We gently mixed both tubes and allowed them to incubate 
at room temperature for 5 minutes. Then, we added the contents of Tube 1 to Tube 2, for 
a total volume of 400 µL. We again mixed carefully and incubated for 20 minutes at 
room temperature. Following the incubation, we added 1.6 mL of antibiotic-free DMEM 
to the mix for a final volume of 2 mL transfection media and a final siRNA concentration 
of 25 nM. The transfection media was added dropwise to the cells and incubated for 24 
hours. For optimal knockdown, fresh media would be added the following day and the 
incubation was continued for a minimum of an additional 48 hours, allowing for a total of 




2.6 – Molecular Biology: 
 
 In order to thoroughly address the goals involved in this project, numerous 
experiments were performed which required a number of different plasmids in several 
combinations. Thus, when identifying the functions of specific proteins, as well as effects 
of proteins on other protein-protein interactions, it was critical that our over-expression 
studies have proteins with different epitope tags. In order to address this, a number of 
molecular biology techniques were performed which include the following: restriction 
enzyme digests, DNA ligations, agarose gel electrophoresis, bacterial transformations, 
and plasmid preparation and purification. 
 
2.6.1 – Restriction Enzyme Digests: 
 
 In order to generate DNA plasmids with different epitope tags, plasmids of 
interest must be subcloned into different expression vectors. In turn, all DNA subcloning 
requires restriction enzymes to shuttle DNA fragments from one vector to another. All of 
the enzymes used in this project were purchased from New England Biolabs® Inc. 
(Ipswich, MA). When performing restriction enzyme digests, reactions would consist of 
our DNA of interest, enzymes with their optimal buffers, and BSA when necessary. 






2.6.2 – Agarose Gel Electrophoresis: 
 
 DNA from restriction enzyme digests were run on 1% agarose gels in order to 
separate our linearized fragments of interested according to size. Agarose gels were made 
by adding 0.5 grams of SeaKem LE agarose, purchased from Lonza (Basel, Switzerland) 
(Cat. #50004), into 50 mL of 1X TAE buffer (Tris-Base, Acetic Acid, EDTA) purchased 
from MediaTech (a Corning subsidiary) (Cat. #46-010-CM), giving a final concentration 
of 1% gel by weight. In order to make the gel, the agarose/TAE solution had to be 
melted. After melting, but before casting, 2 µL of ethidium bromide (Invitrogen) was 
added and mixed well. The ethidium bromide will then intercalate into our linear DNA 
allowing for the visualization of DNA using a UV box. Gels were then loaded and ran at 
approximately 85 volts to allow for separation of the relevant DNA fragments. In the 
instance where DNA fragments needed to be re-annealed to other vectors via DNA 
ligations, the retrieval of DNA from the agarose gel was required. In such cases, DNA 
bands were cut out and purified using a GenElute™ column (purchased from Sigma, Cat. 
#56500) according to the manufacturer’s protocol. 
 
2.6.3 – DNA Ligation: 
 
 Following restriction enzyme digests, agarose gel electrophoresis and DNA 
purification, DNA ligation reactions were performed in order to recombine DNA 
fragments into our vectors of interest. Generally, a 3:1 molar ratio of vector backbone 
fragment to the DNA fragment containing our gene of interest was used in order to 
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achieve efficient ligations. The two DNA fragments (though the double digest of human 
Rb contained three fragments) were added to eppendorf tubes along with 1µL of 10X 
ligation buffer, 1 µL of T4 DNA ligase enzyme (both buffer and ligase were purchase 
from New England Biolabs®), and 5 µL of molecular grade water were added, making a 
total ligation mixture volume of 10µL. The ligation reaction was mixed thoroughly and 
was allowed to incubate overnight in a 10-15°C water bath. 
 
2.6.4 – Bacterial Transformation: 
 
 Chemically competent DH5α were purchased from Invitrogen (Cat. #18265-017) 
and were used for both whole plasmid as well as complete ligated plasmid 
transformations. In order to transform a plasmid into these bacteria, approximately 100 
ng of whole plasmid (or typically 2-5 µL of a completed ligation reaction performed as in 
section 2.7.3) was mixed with 30 µL of DH5α bacteria and incubated on ice for 30 
minutes. The bacteria/plasmid mixture was placed into a 42°C water bath for 30 seconds 
in order to “heat shock” the bacteria, in turn allowing the plasmid DNA to efficiently 
enter the bacteria. After heat shock, the mixture was placed back on ice for an additional 
2 minutes. Then, 250 µL of SOC media (Corning Cellgro Cat# 46-003-CR) was added to 
the mixture and incubated in a 37°C water bath for 1 hour. After this incubation the 
mixture was plated on LB agar plates containing the relevant antibiotic depending upon 
the resistance marker of the plasmid (either Ampicillin with a concentration of 100µg/mL 
or Kanamycin at a concentration of 50µg/mL). For whole plasmid transformations, 50 µL 
of the final mixture would be added to the LB agar plate; however, for transformations of 
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DNA ligation, the entire volume of the transformation would be added to two plates (we 
would add 125 µL per plate on two separate plates), as the transformation efficiency from 
DNA ligations would be far less than whole plasmid transformations. The plates were 
placed in a 37°C incubator overnight. 
 
2.6.5 – Plasmid Purification: 
 
 Following a successful plasmid transformation, individual colonies from the LB 
agar plates would be selected and grown in LB broth media supplemented with the 
relevant antibiotic at the concentrations listed in section 2.7.6, and were incubated using a 
37°C shaker at 300 RPM. The colonies were expanded to either 5 mL overnight cultures 
for mini-prep (small scale) purification; however, for midi-prep (large scale) purification, 
colonies expanded to a 5 mL culture for approximately 8 hours were then added to 75 mL 
of LB broth media and incubated at 37°C overnight. DNA plasmids were extracted and 
purified using either mini-prep (purchased from Qiagen, Cat. #27106) or midi prep kits 
(purchased from Sigma, Cat. #NA0200-1KT). Both mini- and midi-prep plasmid 
purification techniques were performed following the manufacturer’s protocols. Once the 
plasmid purifications were complete, we obtained the plasmid concentrations using a 







2.7 – Biological Assays: 
 
 Attempting to address the hypotheses of this project required the use of several 
state of the art biological techniques and assays. Some of the important goals involved 
identifying novel protein-protein interactions, studying protein stability as well as post-
translational modifications, and induction of cellular senescence. The biological assays 
used to answer these questions included the following: immunoprecipitations, western 
blot analysis, luciferase assays, and senescence assays. The detailed explanations of how 
these assays were performed, as well as data analysis resulting from these assays, are 
listed below. 
 
2.7.1 – Immunoprecipitations: 
 
 One of the most common and applicable techniques used to study protein-protein 
interactions is the coimmunoprecipitation assay. This technique involves agarose beads 
that typically have an antibody conjugated to them, which allows for the precipitation of 
a particular protein. By pulling down proteins of interest using such antibody-conjugated 
beads, one can look for the presence of other proteins that interact with it. From a 
theoretical standpoint, coimmunoprecipitations are considered relatively straightforward; 
however, such a technique can be quite difficult, especially at the endogenous, 
physiological level. Detailed below are procedures involved for coimmunoprecipitations 




2.7.1.1 – Immunoprecipitation of Over-Expressed Proteins 
 
 Coimmunoprecipitations of over-expressed proteins were generally performed 24 
hours post-transfection (as described in Section 2.6) of cells that were plated in 60mm 
dishes. Cells were lysed in 300µL of Modified RIPA buffer (in some cases, more or less 
might be used depending upon cell confluency), which consists of 50mM Tris-HCl 
pH7.4, 200mM NaCl, and 1% NP-40. Modified RIPA buffer was supplemented with a 
protease inhibitor cocktail (Sigma) and 1 mM sodium orthovanadate. Cells were 
harvested using a cell scraper, transferred to eppendorf tubes, and placed on a rotator for 
4 hours at 4°C. After the incubation, each sample was syringed 6-8 times using a 25 
gauge syringe needle, followed by a max speed centrifuge for 3 minutes at 4°C. The 
supernatant was removed from the insoluble pellet, placed in a new eppendorf tube, and 
quantified using a Bio-Rad protein quantification assay (Cat. #500-0006). Typically, 1 
mg of protein was used and additional Modified RIPA buffer was added to each sample 
to make a total volume of 1 mL (giving us consistent samples of 1 mg/mL). Then, 
agarose beads with the relevant epitope tag were added according to the respective 
manufacturer protocol: either 5 µL of GFP (GFP-Trap® Beads from Allele 
Biotechnology, Cat. #ABP-NAB-GFPA100), HA (Sigma, Cat. #A2095-5ML), or FLAG 
(Anti-Flag M2 Affinity Gel from Sigma, Cat. #A2220-5ML) conjugated agarose beads 
were used per sample. In all coimmunoprecipitation experiments using such beads, 
lysates were rotated overnight at 4°C. The following day, the immunoprecipitations were 
centrifuged for 2 minutes at 3000 RPM using a refrigerated centrifuged to pellet down the 
beads. The supernatant was removed and the beads were washed with 500 µL of 
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Modified RIPA buffer. This washing procedure was repeated a total of three times. At the 
last wash step, the beads were re-suspended in 12 µL of RIPA buffer and 4µL of 4X 
NuPAGE LDS sample running buffer. The IPs, along with 50 µg of whole cell lysate per 
sample, were run on a SDS-PAGE gel and analyzed by western blot as described in 
Section 2.8.2. 
 
2.7.1.2 – Immunoprecipitation of Endogenous Proteins: 
 
 As endogenous proteins do not have epitope tags that can be immunoprecipitated 
using antibody-conjugated beads, the protocol for coimmunoprecipitation of endogenous 
proteins varies to the one used for over-expressed proteins. Again, cells were lysed in 
Modified RIPA buffer; however, in this particular case 3 mg of total purified protein was 
placed in a final volume of 1 mL (protein lysate plus Modified RIPA buffer). First, a 
primary antibody against the protein of interest was added and rotated at 4°C overnight. 
The following day, 15 µL of an agarose conjugated secondary antibody (Rockland Cat. 
#00-8811-25) was added and rotated for 4 hours at 4°C as to bind to the primary antibody 
that is now attach to the protein of interest. The agarose beads were again washed three 
times with Modified RIPA buffer as previously described (Section 2.8.1.1). Following 
the wash steps, the beads were resuspended in 12 µL of RIPA buffer and 4 µL of 4X 
NuPAGE LDS sample running buffer. The immunoprecipitations, along with their 
relevant controls (which included lysate with no primary antibody and buffer with 




2.7.2 – Western Blotting: 
 
 Whole cell lysates, as well as any immunoprecipitation samples, were combined 
with a 4X LDS sample buffer purchased from Invitrogen (Cat. # NP0007) made in the 
following manner: 450 µL of LDS sample buffer plus 50 µL of β-Mercaptoethanol 
purchased from Sigma (Cat. # M6250-100ML). The 4X LDS sample buffer was added to 
sample to give a final concentration of 1X. Whole cell lysates and IPs (which were 
vortexed thoroughly) were heated at 95°C for 10 minutes in order for efficient 
denaturation of protein. Once the protein samples were prepared, they were loaded on a 
pre-cast 10% Bis-Tris Polyacrylamide Gel obtained from Invitrogen (Cat. #NP0302BOX) 
and was filled with 1X MOPS SDS Running Buffer (Cat. #NP0001). All protein gels 
were run at 120 Volts until the gels had run to completion (indicated by the loading dye 
reaching the bottom of the gel). The gel was then removed from the casting tray and 
prepared for the transfer phase. 
 Protein gels were transferred onto a 0.2 µm pore size nitrocellulose membrane 
using a complete immersion (wet) transfer in 1X Transfer Buffer (Cat. #NP0006-1), 
which was made in the following manner: 50 mL of 20X Transfer Buffer, 200 mL of 
methanol, and 750 mL DI water. The prepared transfer buffer was always pre-chilled in a 
-20°C freezer before use. All protein gels were transferred at 35 volts for approximately 
three hours. 
 Following the transfer phase, nitrocellulose membranes would be washed in 1X 
TBST solution for 5 minutes and then blocked in a 5% milk in 1X TBST solution for 1 
hour. After blocking, the membranes (blots) would be incubated in primary and 
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secondary antibodies as previously described in Section 2.3. Between primary and 
secondary antibodies, as well as after secondary antibody removal before West PICO 
ECL detection, blots were washed in 1X TBST 3 times for 5 minutes and one additional 
time for 10 minutes. Blots were immersed in West PICO ECL solution for 2 minutes and 
exposed to chemi-luminescent detection film purchased from MidSci™ (Valley Park, 
MO) (Cat. #EBA45). 
 
2.7.3 – Generation of Stable Rb Knockdown Cell Lines: 
 
 In order to effectively study the significance of Rb in NORE1A mediated 
senescence, we generated a matched pair of A549 cell lines that were either wild-type or 
stably knocked down for Rb expression. To generate Rb knockdown cells, 293FT cells 
were transfected with the pLKO-Rb knockdown constructs (described in Section 2.1) and 
a mixture of the viral packaging plasmids pLP1, pLP2 and pLP/VSVG (Invitrogen) at a 
ratio of 1:3, using JetPRIME™ transfection reagent. Approximately 48 to 72 hours 
following transfection, supernatant containing viral particles was harvested and clarified 
by centrifugation at 2000 RPM for 5 minutes. 2 mL of the clarified viral supernatant 
containing 4 g/mL polybrene was added to A549 cells and the cells incubated for 12-
16hr at 37C. This viral transduction step was repeated once more. After the second 
transduction step, cells stably transduced with the knockdown constructs were selected in 
1g/ml of puromycin purchased from Sigma (Cat. #P8833-10MG) and used as an early 
passage pooled population. All aspects involving the generation of Rb knockdown cell 
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lines were carried out by Dr. Howard Donninger, and the validation of the matched 
paired cell system was performed by western blot analysis. 
 
2.7.4 – Senescence Assays: 
 
 The main focus of this project was to elucidate the mechanisms by which 
NORE1A can promote the induction of senescence. While there are several established 
markers of senescence, the gold standard used to study cellular senescence is by an 
increase in β-galactosidase activity that can be detected at a sub-optimal pH (246). For 
the purposes of this project, we purchased a senescence detection kit from BioVision Inc. 
(Milpitas, CA) (Cat. #K320-250) that can be used to detect β-galactosidase activity from 
mammalian cells grown in culture. We performed senescence assays in MEFs (wild-type 
MEFs have the senescence machinery intact) and A549s (that can be induced for 
senescence by NORE1A transfection) (20). For MEFs and A549s, approximately 50,000 
cells were seeded per well in 12-well plates. The day after plating, cells were transfected 
with the relevant expression constructs (as described in Section 2.5), and fresh media 
added every 24 hours for 72 hours post-transfection. Cells were then stained for β-
galactosidase as recommended by the manufacturer’s protocol. The scoring of the assay 
was performed by counting five random fields of view per well, doing a ratio of the 
number of β-galactosidase positive stained cells to the total number of cells in the field of 
view. This allows for a percentage of cells undergoing senescence. For senescence assays 
involving PP1A siRNAs, the siRNAs were transfected first and the transient transfection 
of NORE1A would be performed the following day. These cells were incubated for an 
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additional 72 hours before β-galactosidase staining. For any senescence assay that was 
performed in this dissertation, the relative expression of GFP-tagged NORE1A was taken 
48 hours post-transfection to ensure consistent transfection efficiency throughout the 
experiment. 
 
2.7.5 – Luciferase Assays: 
 
 Luciferase assays were performed using reagents using the LightSwitch™ 
luciferase assay kit with a corresponding luciferase reporter construct containing the IL-6 
promoter generated by Active Motif (Carlsbad, CA). A549 +/- Rb cells (described in 
Section 2.8.2) were plated at a concentration of 5,000 cells per well in a 96-well plate. 
These cells were transfected with the IL-6 promoter luciferase construct in the presence 
or absence of GFP-NORE1A, and were incubated for 48 hours. Before performing the 
luciferase assay, pictures were taken to show consistent expression of GFP-vec/NORE1A 
throughout the experiment. Cells were lysed according to the manufacturer’s protocol, 
and the samples were read using a Lumat LB 9507 from Berthold Technologies (Oak 
Ridge, TN). The data was analyzed using the Relative Luciferase Units (RLU). 
 
2.8 – Image Acquisition, Processing, and Statistical Analysis: 
 
 A Pharos FX plus Molecular Imager from BioRad (Hercules, CA) was used to 
digitize images prior to quantification using Quantity One software (BioRad). Figures 
were compiled using Photoshop software (Adobe). All data are reported as mean ± 
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standard deviation. Difference between treatment groups were tested using a two-sided 












RAS REGULATES RB VIA NORE1A 
 
3.1 – Introduction: 
 
Ras mutations are the most frequent oncogenic events in human cancer and can be 
found in approximately 30% of all human cancers (247). In experimental systems, 
activated forms of Ras can be powerfully transforming, and transgenic animal models 
have validated the role of Ras activation in tumorigenesis (8,248). However, despite the 
extensive evidence linking Ras to transformation and tumor development, activated Ras 
can also promote a state of irreversible cell cycle arrest called oncogene induced 
senescence (159,249). This tendency for deregulated Ras activity to provoke senescence 
can be observed in Ras driven tumors (246). It appears that senescence provides a potent 
barrier to suppress the development of Ras driven cancer, as malignant tumors lose the 
senescence phenotype (246). The exact mechanisms by which Ras can promote 
senescence are not completely understood, but it appears the main Ras senescence 
pathways involve the p53 and Rb tumor suppressors (250). Initial evidence in mouse 
embryonic fibroblasts (MEFs) suggests that loss of functional p53 or Rb pathways alone 
is sufficient for Ras to bypass senescence (159). More recent studies show that in vivo, 
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suppression of p53 function (251) or Rb (252) enhances Ras mediated transformation in 
murine systems. However, human systems may require inactivation of both p53 and Rb 
for full senescence evasion (253). Thus, inactivation of p53 and Rb senescence pathways 
may be essential for Ras-induced transformation. 
In addition to the classic trio of growth promoting Ras effector proteins, Raf, PI-3 
kinase and RalGDS, Ras also interacts with growth suppressing effector proteins, 
including NORE1A (RASSF5) (6,254). NORE1A is a member of the RASSF family of 
tumor suppressors that is frequently down-regulated during tumor development, and its 
inactivation has been linked to a rare familial cancer syndrome (13,15,18). NORE1A 
binds directly to Ras (19) and is thought to act as a scaffolding protein as it lacks any 
apparent enzymatic activity. NORE1A connects Ras to the pro-apoptotic Hippo pathway 
(19) and has apoptotic properties (12). NORE1A
-/-
 MEFs are predisposed to Ras-induced 
transformation, unlike wild-type MEFs which require inactivation of p53 or Rb to allow 
transformation by Ras (255). Furthermore, up-regulation of Ras activity in primary 
tumors is often correlated with inactivation of NORE1A (15,256). Thus, NORE1A acts 
as a potent barrier against aberrant Ras signaling, and loss of NORE1A allows Ras to 
circumvent its own growth inhibitory properties, shifting the balance of Ras activity 
towards transformation (20). 
We have recently shown that NORE1A is a powerful Ras senescence effector that 
acts via p53 (20). NORE1A forms an endogenous, Ras regulated complex with the kinase 
HIPK2, which can regulate both the phosphorylation and the acetylation of p53. In turn, 
NORE1A scaffolds HIPK2 to p53 and stimulates pro-senescent p53 acetylation. 
Although we found that NORE1A induced senescence is heavily dependent upon p53, we 
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noticed that NORE1A retained partial senescence inducing activity even when nearly all 
detectable p53 had been eliminated from the system (20), suggesting that additional 
mechanisms are required for the effects of NORE1A on senescence to fully manifest. 
In addition to p53, Ras can promote senescence induction by activating the Rb 
pathway. The Retinoblastoma (Rb) gene was the first identified tumor suppressor gene in 
rare cases of pediatric tumors of the retina called retinoblastoma (199,222,257). 
Furthermore, alterations in the Rb gene or inactivation of the Rb protein have been 
identified in a variety of human cancers (258,259), and it is now widely accepted that the 
inactivation of the Rb protein may be one of the most frequent events in cancer (260). In 
addition to its important function in regulating the cell cycle, recent evidence points to Rb 
having critical functions in other biological processes, including chromosomal stability, 
regulation of apoptosis, and oncogene induced senescence (159,261,262).  Inactivation of 
Rb in vitro or in vivo suppresses Ras-induced senescence (159,252), implicating Rb as an 
important effector of Ras mediated senescence.  Thus, while it appears that Ras activates 
senescence, in part, via Rb, exactly how Ras modulates Rb activity remains unclear. 
Rb regulation is complex and involves both inhibitory phosphorylation and 
activating dephosphorylation events. While the mechanisms of Rb phosphorylation by 
cyclin-dependent kinases are well characterized (231), the processes that activate Rb by 
dephosphorylation remain unclear.  Recent reports have shown that the phosphatases PP1 
and PP2A play important roles in the mammalian cell cycle (263-265). Moreover, it has 
been shown that PP1 phosphatases can act on Rb to promote the formation of the active, 
hypophosphorylated form of the protein (232,236). Intriguingly, PP1A enzymatic activity 
can be regulated by Ras (237). Thus, PP1A might serve as the link between Ras and Rb, 
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and Ras may, in part, promote senescence by activating PP1A, thereby promoting the 
dephosphorylation and activation of Rb (22). Exactly how Ras stimulates the activity of 
PP1A towards Rb remains obscure. 
 PP1A, a key regulator of Rb activity, was first detected in complex with 
NORE1A in a yeast two-hybrid system (23), and since we have recently established that 
NORE1A mediated Ras-induced senescence is only partly driven by p53, we sought to 
determine if NORE1A could also be modulating senescence by regulating Rb function. 
We now show that NORE1A regulates the dephosphorylation of Rb by forming an 
endogenous, Ras regulated, complex with PP1A, scaffolding it to Rb and enhancing the 
Rb/PP1A complex. Moreover, suppression of Rb suppresses NORE1A induced 
senescence. Thus, we now identify a powerful new mechanism by which Ras can induce 
senescence via regulating the phosphorylation status of Rb. Therefore, NORE1A acts as a 
critical node linking both p53 and Rb to Ras. This may explain why Ras driven tumors 
often exhibit reduced NORE1A expression (256). 
 
3.2 – Results: 
 
NORE1A forms an endogenous, Ras regulated complex with PP1A –NORE1A is 
primarily localized to the nucleus (20), and has been observed to shuttle between the 
cytoplasmic/nuclear cell fractions (266). However, the localization pattern of PP1A is 
more complex. PP1A exhibits diffuse expression in the cytoplasm and the nucleoplasm, 
but also accumulates in unidentified nuclear bodies (267). Since NORE1A also occurs in 
nuclear speckles, we determined whether NORE1A and PP1A co-localized in 
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mammalian cells using transient transfections of the fluorescently tagged proteins. We 
found that a pool of GFP-PP1A specifically co-localized with KATE-NORE1A in the 
nucleus (Figure 6). The KATE protein is a far red fluorescent protein that gives bright 
far-red fluorescence to easily detect proteins engineered to contain a fused KATE tag 
(268,269). An empty KATE vector was used as a negative control. 
To determine if NORE1A and PP1A can be found in a complex, we performed 
coimmunoprecipitations in HEK-293T cells co-transfected with NORE1A and PP1A in 
the presence or absence of activated Ras. We found that NORE1A does complex with 
PP1A. Furthermore, the results show that the interaction of NORE1A and PP1A is 
significantly enhanced in the presence of activated Ras (Figure 7A). Further analysis 
confirmed that endogenous NORE1A could be coimmunoprecipitated with endogenous 
PP1A from the HepG2 human liver hepatocellular carcinoma cell line (Figure 7B), 
confirming that the NORE1A/PP1A interaction is physiologically relevant. 
 
Ras/NORE1A Stabilize PP1A – While studying the effects of Ras on the 
NORE1A/PP1A interaction, we observed an increase in the levels of PP1A in whole cell 
lysates in the presence of Ras and NORE1A.  We hypothesized that Ras/NORE1A could 
be promoting PP1A stability. To address this, we analyzed the effects of NORE1A and 
Ras on PP1A protein stability by using cycloheximide treatment after transient 
transfections in HEK-293 cells. While the results show that Ras or NORE1A individually 
did not seem to promote the stability of PP1A, the presence of both Ras and NORE1A 
together lead to a statistically significant (P<0.05) increase in PP1A expression, even 24 




















Figure 6. Exogenously expressed NORE1A and PP1A co-localize in the nucleus. 
COS-7 cells were transfected for 48 hours with GFP-PP1A in the presence or absence of 
KATE-NORE1A. While PP1A can be found throughout the cell, there is an important 
pool of PP1A strongly co-localizing in the nucleus with NORE1A. Representative images 
were taken using an IX50 inverted system microscope (Olympus) and a SPOT camera 
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Figure 7. NORE1A forms an endogenous, Ras regulated complex with PP1A. A. 
Activated Ras enhances the interaction between NORE1A and PP1A. HEK-293T cells 
were co-transfected with expression constructs for PP1A, NORE1A, and activated H- or 
K-Ras for 24 hours. Cells were then lysed and equal amounts of protein extracts were 
immunoprecipitated with anti-GFP. The immunoprecipitates were analyzed by western 
blotting with anti-HA and anti-GFP antibodies. B. NORE1A and PP1A are found in an 
endogenous complex. HepG2 cells were immunoprecipitated (IP) for NORE1A and 
immunoblotted (IB) for PP1A. IgG incubated with HepG2 lysates and Ig/NORE1A 
antibody incubated with lysis buffer served as negative controls. 
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Figure 8. Ras/NORE1A stabilizes PP1A. HEK-293 cells were transfected with PP1A, 
NORE1A, and activated H-Ras expression constructs for 24 hours. The cells were treated 
with cycloheximide (20 µg/mL) and lysed at the indicated times after addition of 
cycloheximide. Levels of PP1A protein were measured by western blot analysis. Shown 
is a representative blot of three independent experiments. The density of the bands was 
quantitated using ImageJ software and relative PP1A expression was calculated after 
normalizing to β-Actin expression. In cells transfected with both NORE1A and Ras, there 
was a statistically significant increase in the levels of PP1A (P<0.05). 
GFP-PP1A: + + + + + + ++++
HA-NORE1A: + + + + +- - ---
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Figure 9. Quantification of the relative PP1A expression in the presence and absence 
of NORE1A and activated H-Ras following cycloheximide treatment. Quantification 
of three independent experiments was performed, which is shown as a representative 
image in Figure 8. Briefly, the blots were quantified densitometrically to calculate the 
relative amount PP1A in the presence or absence of NORE1A and H-Ras-12V following 




cooperate to promote PP1A stability. Since NORE1A regulates the stability of other 
target proteins via the proteasome (194), we sought to determine whether Ras/NORE1A 
may be similarly regulating PP1A stability. We co-transfected HEK-293T cells with 
PP1A  and  an  HA-ubiquitin-1  expression  construct  in  the  presence  and  absence  of 
NORE1A and activated Ras, treated the cells with the proteasome inhibitor MG132, 
immunoprecipitated the PP1A and analyzed the immunoprecipitates for ubiquitinated 
PP1A by western blotting with an anti-HA antibody. Although the levels of ubiquitinated 
PP1A appear reduced in the Ras/NORE1A sample (Figure 10), quantification of multiple 
experiments showed that the apparent decrease was not statistically significant. This 
suggests that the stabilization effect may be independent of the proteasome system. 
 
NORE1A forms an exogenous, Ras regulated complex with Rb – PP1A is a 
phosphatase that binds to Rb and modulates its activity by dephosphorylation (270). 
Since we have now established an endogenous interaction between NORE1A and PP1A, 
it is plausible that NORE1A could be found in a complex with Rb. We first wanted to 
determine if the proteins co-localize in the cells. To address this, we co-transfected COS-
7 cells with GFP-tagged Rb in the presence of either KATE-vector (used as a negative 
control) or KATE-NORE1A for 48 hours. We did find strong co-localization of the two 
proteins within the nucleus (Figure 11A). To confirm that the proteins interact, we co-
transfected HEK-293T cells with NORE1A and Rb in the presence and absence of 
activated Ras and found that NORE1A coimmunoprecipitated with over-expressed Rb, 
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Figure 10. Ras/NORE1A do not significantly alter proteosomal degradation of 
PP1A. HEK-293 cells were transfected with expression constructs for PP1A, NORE1A, 
activated H-Ras and Ubiquitin-1 for 24 hours. The cells were then treated with the 
proteosome inhibitor MG132 for 4 hours, lysed and equal amounts of protein 
immunoprecipitated with anti-GFP. The immunoprecipitates were analyzed by western 
blotting with anti-HA, anti-GFP and anti-FLAG antibodies. The density of the bands was 
quantitated using ImageJ software and the relative amount of ubiquitinated PP1A was 
calculated after normalizing to the total amount of PP1A immunoprecipitated. Although 
there appeared to be less ubiquitinated PP1A in the presence of both NORE1A and 




































































Figure 11. NORE1A complexes with Rb. A. Exogenously expressed NORE1A and Rb 
co-localize in the nucleus. COS-7 cells were transfected for 48 hours with GFP-Rb in the 
presence or absence of KATE-NORE1A. B. NORE1A forms a Ras regulated complex 
with Rb. HEK-293T cells were co-transfected with expression constructs for Rb, 
NORE1A, and activated H-Ras for 24 hours. The cells were then lysed and immuno-
precipitated with anti-GFP. The immunoprecipitates were analyzed by western blotting 
with anti-HA and anti-GFP antibodies. *, P<0.05 compared to cells transfected with 




NORE1A Cooperates with Ras to Scaffold PP1A to Rb – NORE1A is a tumor 
suppressor that is thought to act primarily as a scaffolding molecule, as it has no apparent 
enzymatic activity (15,191,194). We have recently identified a Ras mediated mechanism 
by which NORE1A scaffolds HIPK2 to p53 in order to promote the pro-senescent 
functions of p53 (20). Thus, a similar mechanism may be occurring here where NORE1A 
acts to scaffold PP1A onto Rb in a Ras dependent manner. To test this, we co-transfected 
HEK-293T cells with Rb, PP1A, and NORE1A expression constructs in the presence or 
absence of activated Ras, immunoprecipitated the NORE1A and immunoblotted for the 
presence of both Rb and PP1A. We found that both PP1A and Rb could be found in a 
complex with NORE1A simultaneously, and the levels of both PP1A and Rb in the 
complex with NORE1A increased in the presence of activated Ras (Figure 12). To 
confirm that NORE1A was scaffolding PP1A to Rb, we transfected HEK-293T cells with 
Rb and PP1A, in the presence and absence of NORE1A and activated Ras, and examined 
the effects of Ras and NORE1A on the complex formation between PP1A and Rb. The 
results show that indeed, the Rb/PP1A complex is enhanced by NORE1A, and that this 
effect is further increased in the presence of activated Ras. A representative blot is shown 
in Figure 13 and quantification of two independent experiments is shown in Figure 14. 
Exactly how Ras facilitates the interaction between NORE1A and PP1A and Rb is not 
entirely clear. However, binding of Ras to NORE1A induces a conformational change 
(271), and this may promote the interaction between NORE1A and its binding partners. 
 
NORE1A promotes the dephosphorylation of Rb at Serine 795 – The activity of 
Rb is primarily regulated by its phosphorylation status at several Ser/Thr residues, and Rb 
















Figure 12. PP1A and Rb are found in a Ras regulated complex with NORE1A. HEK-
293T cells were co-transfected with PP1A, Rb, NORE1A and activated H-Ras expression 
constructs for 24 hours. The cells were lysed and equal amounts of protein 
immunoprecipitated with anti-FLAG. The immunoprecipitates were analyzed by western 



















































Figure 13. Ras regulates the interaction between PP1A and Rb via NORE1A. HEK-
293T cells were co-transfected with expression constructs for PP1A, Rb, NORE1A, and 
activated H-Ras for 24 hours. Cells were lysed and immunoprecipitated for GFP-PP1A, 









































































Figure 14. Quantification of the relative fold increase in Rb/PP1A interaction. 
Quantification of three independent experiments was performed, which is shown as a 
representative image in Figure 12. Briefly, the blots were quantified densitometrically to 
calculate the relative amount of Rb found in complex with PP1A. *, P<0.05 compared to 
cells transfected with empty vector, **, P<0.05 compared to cells transfected with either 




NORE1A forms an endogenous complex with PP1A, a key mediator of Rb- 
dephosphorylation, and scaffolds it to Rb, we sought to determine if NORE1A could 
promote the dephosphorylation of Rb. By using a phospho-specific antibody to Ser-795, a 
residue known to be regulated in part by PP1A (272), we examined the effects of 
NORE1A on Rb phosphorylation. In transient transfections of A549 cells (a mutant K-
Ras NORE1A negative, p53 positive lung tumor cell line (17)), we observed that 
NORE1A decreased the phosphorylation of endogenous Rb at Serine 795 (Figure 15A). 
In addition, we examined the phosphorylation status of endogenous Rb in NCI-H1299 
lung cancer cells (mutant Ras positive, NORE1A negative, p53 negative (273)) stably 
expressing NORE1A at more physiological levels (194), and found similar results 
(Figure 15B). To confirm the link between NORE1A and Rb phosphorylation, we 
transiently knocked down NORE1A in HEK-293 cells using two previously validated 
shRNA constructs to NORE1A (20), and found that indeed loss of NORE1A enhanced 
the phosphorylation of Rb at Serine 795 (Figure 16). Thus, it seems that NORE1A may 
be a crucial mediator of Rb function by regulating its phosphorylation status. 
 
Rb is a downstream effector of NORE1A induced senescence – We have recently 
shown that NORE1A is a critical Ras senescence effector that acts by forming a Ras 
regulated complex with p53 (20). However, although suppression of p53 strongly 
impaired the NORE1A senescence phenotype, it did not completely abolish it. This 
suggests that NORE1A may be able to promote senescence via additional mechanisms. 
Since the Rb pathway is one of the most powerful effector pathways of Ras-induced 
senescence, and we have now shown that NORE1A can regulate the dephosphorylation 


























Figure 15. NORE1A promotes Rb dephosphorylation. A. A549 cells, which do not 
express NORE1A, were transiently transfected with GFP-NORE1A for 24 hours. Cells 
were lysed and immunoblotted for Rb phosphorylated at Serine-795 using a S795-
specific antibody. B. NCI-H1299 cells stably expressing NORE1A or an empty vector 
were lysed an immunoblotted for phospho-RB at Serine 795. Shown are representative 












































Figure 16. Loss of NORE1A enhances Rb phosphorylation. HEK-293 cells were 
transiently knocked down for NORE1A expression using two different shRNA constructs 
to NORE1A. The cells were lysed 48 hours following transfection and were immuno-








addition to p53 in order to fully promote its senescent phenotype. To address this 
question, we transfected NORE1A into wild type and Rb
-/- 
MEFs and measured 
senescence by β-galactosidase activity. As we have previously shown, NORE1A induces 
senescence in wild-type MEFs, but in the absence of Rb, NORE1A was unable to induce 
senescence (Figure 17A and B). This suggests that NORE1A requires Rb in order to 
induce senescence in primary murine fibroblasts. 
 A459 cells are a human lung adenocarcinoma cell line that expresses wild type 
p53 and Rb, but do not express NORE1A (17). To confirm the role of Rb in NORE1A 
mediated senescence in human cells, we generated A549 cells that were knocked down 
for Rb using two different shRNAs to Rb (Figure 18). We then transiently transfected 
NORE1A into these cells, and assayed senescence by β-galactosidase activity. As 
expected, NORE1A was able to promote senescence in the cells stably transfected with 
the scramble control, but its ability to drive senescence was severely, although not 
completely, suppressed in the cells knocked down for Rb expression (Figure 19A and 
B). To substantiate that the elevated levels of β-galactosidase staining observed in these 
cells was senescence-related, we measured effects on IL-6 expression, an additional well-
established marker of senescence (246). NORE1A induced a significant (P<0.05) 
increase in IL-6 promoter activity in the A549 cells, which was abrogated in the absence 
of Rb (Figure 20). Thus, in addition to p53, NORE1A also appears to act via Rb to fully 
promote senescence. 
 
 PP1A-mediated dephosphorylation of Rb is required for NORE1A Induced 





















































Figure 17. Loss of Rb significantly impairs NORE1A mediated senescence in MEFs. 
Wild-type and Rb
-/-
 MEFs were transfected with 1 µg pcDNA-HA-Vector or NORE1A. 
Cells were incubated for 72 hours before assaying for β-galactosidase activity. *P≤0.05 


























Figure 18. Generation of human lung cancer A549 +/- Rb matched pair cell system. 
To study the effects of NORE1A on Rb and senescence, we generated a matched pair cell 
system that would be wild-type or knocked down for Rb expression. The system was 
generated using two different lentiviral expression constructs containing shRNAs to Rb. 



























































































Figure 19. Rb is a downstream effector of NORE1A induced senescence in human 
cells. A. Stable scrambled or sh-Rb transduced A549 cells were transfected with 1 µg 
GFP-NORE1A. After 72 hours, the cells were assayed for β-galactosidase activity. 
*P<0.05 compared with scrambled control transfected cells. B. Representative images of 















































































Figure 20. Rb is an effector of NORE1A induced IL-6 promoter activity. A. Control 
and A549 cells stably knocked down for Rb described previously were co-transfected 
with GFP-NORE1A and an IL-6 promoter luciferase reporter construct. Luciferase 
activity was measured 48 hours after transfection using a LightSwitch Luciferase Assay 




complex formation with Rb, promotes the dephosphorylation of Rb and requires Rb for 
senescence. To fully substantiate that the NORE1A mediated dephosphorylation of Rb by 
PP1A is required for NORE1A induced senescence, we examined the ability of NORE1A 
to promote the dephosphorylation of Rb and promote senescence in the absence of PP1A. 
In the absence of PP1A, both NORE1A mediated dephosphorylation (Figure 21) and 
senescence (Figure 22) were severely impaired, confirming that dephosphorylation of Rb 
via PP1A is required for NORE1A mediated senescence. 
 
3.3 – Discussion: 
 
 Oncogenic Ras mutations are critical drivers of transformation via promotion of 
mitogenic signaling pathways (6). Paradoxically, Ras also regulates growth inhibitory 
pathways such as apoptosis and senescence (148,159,274). Ras-induced senescence is a 
major defense mechanism suppressing Ras driven transformation, and loss of functional 
senescence pathways is necessary for Ras to manifest its full transforming potential 
(246,275). While recent studies have confirmed the significance of Ras-induced 
senescence in vivo, the mechanisms by which Ras can promote a senescent phenotype 
both in vitro and in vivo remain poorly defined (246,276,277). 
 Two pathways that have been identified as key players in oncogene induced 
senescence involve the p53 and Rb tumor suppressors. Early studies in primary rodent 
cells suggested that loss of either the p53 or the Rb pathways was sufficient for Ras to 
bypass senescence and promote transformation (159). In contrast, the loss of one of these 





































































Figure 21. Loss of PP1A impairs NORE1A induced dephosphorylation of Rb. A. 
A549 cells were transiently knocked down for PP1A expression using a validated pool of 
PP1A siRNA. The cells were transfected with GFP-NORE1A and 24 hours later, lysed 
and immunoblotted for phosphor-Rb at Serine 795, Rb, PP1A, and NORE1A. B. 
Quantification of two independent experiments was performed. Blots were quantified 
densitometrically to calculate the relative amount of Rb phosphorylation at Ser-795. *, 
P<0.05 compared to vec/scrm transfected cells. **, P<0.05 compared to vec/scrm and 





































































Figure 22. PP1A is required for NORE1A induced senescence. A. A549 cells were 
transiently knocked down for PP1A as previously described and transfected with GFP-
NORE1A. 72 hours later, cells were assayed for β-galactosidase activity. *, P<0.05 
compared with control cells transfected with vector, **, P<0.05 compared to si-Scrm 






have shown that the activation of both the p53 and the Rb pathways is essential for 
induction of senescence in a variety of human cell lines (159,164,253,278,279), and 
furthermore, cross-talk between the p53 and Rb pathways could allow for additional 
protection against oncogenic Ras bypassing senescence and promote tumorigenesis (250). 
Until now, the mechanisms by which Ras regulates the p53 and Rb pathways to drive 
senescence has been unclear. 
 NORE1A (RASSF5) is a member of the RASSF family of tumor suppressors 
(15). Like other members, it binds directly to Ras and serves as an effector to promote its 
growth inhibitory properties (12,19). The best characterized member of the RASSF 
family is RASSF1A, which shares considerable homology to NORE1A. RASSF1A binds 
and activates MST kinases, which then feed into the Hippo pathway to regulate the 
transcriptional co-activators YAP1, YAP2 and TAZ.  However, although NORE1A also 
binds MST kinases (19), it does not seem to activate them (280). Moreover, deletion 
mutagenesis has shown that the interaction of NORE1A with MST kinases is not required 
for its ability to inhibit cellular growth (17). This suggests that NORE1A may be 
different to RASSF1A, and act via non-Hippo components.   
 By inducing physiological expression levels of NORE1A in cells, we found 
NORE1A plays a key role in p53-mediated cell-cycle arrest (191). This led us to 
determine that NORE1A is a potent senescence effector of Ras that precisely regulates 
the post-translational modification code of p53 (20). NORE1A forms a Ras-regulated 
complex with p53 and the kinase HIPK2.  This scaffolding event is an essential 
component of Ras-induced senescence, and results in the enhanced acetylation of p53 at 
K320 and K382 residues.  Acetylation of p53 at these residues activates pro-senescent 
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transcriptional programs (20,281). However, we noted that although suppression of p53 
severely reduced NORE1A induced senescence, it did not completely abolish it (20). 
Thus, the role of NORE1A in Ras-induced senescence is likely more complex and may 
work through additional senescence pathways. 
 We hypothesized that NORE1A may also be able to promote senescence by 
regulating the Rb pathway, the other powerful senescence pathway in oncogene induced 
senescence. Indeed, we found that loss of Rb in both MEFs and human cells suppressed 
the powerful senescence phenotype promoted by NORE1A. Interestingly, the suppression 
of either Rb or p53 alone in A549 cells did not completely inhibit NORE1A induced 
senescence, consistent with the notion that human cells require the loss of both the p53 
and Rb pathways in order to fully bypass senescence.  
 One of the main regulators of Rb activity is the PP1A phosphatase (282,283). 
PP1A has been implicated in Ras-induced senescence (22) and Ras has been shown to 
control the catalytic activity of PP1A (237). As PP1A specificity is often controlled by 
targeting proteins (25), we wondered if NORE1A might serve as a direct connection 
between Ras, PP1A and Rb. We found that NORE1A forms an endogenous, Ras 
regulated complex with the phosphatase PP1A.  As PP1A has been detected in complex 
with NORE1A in a yeast two-hybrid system, the interaction is likely to be direct (23). 
Furthermore, we found that NORE1A appears to scaffold PP1A to Rb in a Ras dependent 
manner, as NORE1A could be co-precipitated with Rb and Ras/NORE1A enhanced the 
interaction between PP1A and Rb.  The scaffolding of Rb to its phosphatase results in Rb 
dephosphorylation, a pro-senescent event (24). The exact mechanism by which Ras 
activates this NORE1A-PP1A-Rb axis is not entirely clear since Ras is found 
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predominantly on the cell membrane and the NORE1A/PP1A/Rb complex is located 
primarily in the nucleus. One possibility involves a Ras-induced conformational change 
of NORE1A (271) that enables it to interact with PP1A and/or Rb, and then shuttle them 
as a complex into the nucleus via various nuclear transport proteins (266). Another 
possible mechanism may involve additional Ras signaling pathways that act upon nuclear 
NORE1A to activate it, thereby inducing it to complex with PP1A and Rb. Interestingly, 
a pool of Ras has also been found located in the nucleus (284,285), raising the possibility 
that NORE1A/Ras stimulation of PP1A/Rb is entirely nuclear. 
During these studies, we also noticed that NORE1A seems to modulate the 
stability of PP1A. Recent studies have shown that the ubiquitin ligase mdm2, a negative 
regulator of Rb that contributes to tumorigenesis in part by destabilizing Rb (286), can be 
found in an endogenous complex with PP1A (287), though the effects of mdm2 on PP1A 
stability have not been elucidated. Interestingly, NORE1A has been shown regulate the 
degradation of specific mdm2 targets (288). Thus, NORE1A could be regulating PP1A 
stability through its interaction with mdm2, potentially by antagonizing the 
ubiquitination/degradation properties of mdm2. 
 PP1A is not an Rb-specific phosphatase and can regulate the functions of a 
variety of proteins in the cell by modulating their phosphorylation status. The specificity 
of PP1A is dictated by targeting proteins (25). Our data suggests that NORE1A may 
serve as a Ras regulated PP1A-targeting protein, directing PP1A to a specific set of 
substrates, such as Rb. This may provide a novel mechanism whereby NORE1A mediates 
its tumor suppressor function through modulating specific protein phosphorylation. 
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Further studies will be necessary to identify any additional NORE1A targeted PP1A 
substrates. 
 Our data provide evidence that NORE1A provides a major link between Ras and 
Rb. Activated Ras signaling promotes the association of PP1A to Rb via NORE1A, 
resulting in the activation of Rb and senescence. In the absence of NORE1A, PP1A 
cannot effectively scaffold to Rb and activate it, resulting in senescence bypass and 
allowing the growth promoting effects of aberrant Ras signaling to predominate (Figure 
23). Thus, NORE1A acts as a double-barreled Ras senescence effector that connects Ras 
to the two major senescence effectors in human cells, p53 (20) and Rb. This may explain 
why NORE1A is such a powerful senescence effector and why it is so frequently down-
































Figure 23. Schematic representation of the newly identified Ras/NORE1A/Rb 
pathway. Our data points to a novel Ras/NORE1A/Rb pathway whereby Ras promotes 
NORE1A mediated scaffolding of PP1A to Rb to promote its dephosphorylation. This 
results in Rb activation and subsequently activates the senescence machinery. Loss of 
NORE1A inhibits the proper dephosphorylation of Rb, in turn suppressing senescence 













NORE1A REGULATES ADDITIONAL RB POST-TRANSLATIONAL 
MODIFICATIONS AND PROMOTES ITS STABILITY 
 
4.1 – Introduction: 
 
 While Ras oncoproteins have potent transforming properties, they can also 
activate important growth inhibitory pathways, including apoptosis and senescence 
(148,159,274,289). Work performed by Donninger and colleagues has recently identified 
NORE1A as a key component of Ras-driven senescence by regulating the pro-senescent 
post-translational modifications of p53 (20). The link between Ras/NORE1A and p53 
appears to be primarily the kinase HIPK2, which has been shown to regulate apoptosis by 
directly phosphorylating p53 at Serine 46, in turn enhancing the affinity of p53 for pro-
apoptotic gene promoters (290,291). In addition, HIPK2 can recruit acetyltransferases 
CBP/p300 and PCAF, which can acetylate p53 and modulate its transcriptional activity 
(291-293). Acetylation of p53 at Lysine 382, in combination with phosphorylation at 
Serine 46 shifts p53 towards apoptosis; however, without the phosphorylation of Serine 
46, the acetylation of Lysine 382 drives p53 away from apoptosis and pushes it towards 
the induction of senescence (281,294). NORE1A forms an endogenous, Ras-regulated 
109 
 
complex with HIPK2, in turn promoting senescence not only by acetylating p53 at Lysine 
382, but also by suppressing the phosphorylation of p53 at Serine 46 (20). It was also 
shown that NORE1A can promote the acetylation of p53 at Lysine 320 (20), which has 
been reported to enhance p53 association with the p21
CIP1
 promoter, in turn enhancing its 
expression which can ultimately lead to senescence (295). Thus, NORE1A can regulate 
the post-translational signature of p53 in order to activate senescence. 
Rb is the other critical tumor suppressor involved in Ras-induced senescence. In 
murine cells, abrogation of either p53 or Rb seems to be sufficient to suppress 
senescence; however, in human systems, both the p53 and Rb pathways must be 
inactivated in order for Ras to bypass senescence and drive transformation (253). As is 
the case with p53, Rb undergoes numerous post-translational modifications that regulate 
its tumor suppressive functions (296). Although the phosphorylation of Rb has been 
extensively studied, the significance of non-phosphorylation post-translational 
modifications of Rb, including the acetylation and SUMOylation, remains quite unclear. 
It has been proposed that active Rb is both acetylated and hypophosphorylated. 
Rb has recently been shown to be acetylated at the C-terminus by p300, which hinders 
the phosphorylation of Rb by cyclin-dependent kinases (297), leading to the maintenance 
of Rb in its active, hypophosphorylated form. As a result, such cells are maintained in a 
growth arrested state. It is believed that some unknown cellular protein functions to 
bridge p300 and Rb into a multi-protein complex to facilitate Rb acetylation. In addition 
to p300, it has been recently shown that the p-300 Associated Factor (PCAF) can mediate 
Rb acetylation, as Rb interacts directly with the acetyltransferase domain of PCAF in 
vitro and can associate with PCAF in differentiated cells (298). PCAF acetylates Rb to 
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induce Rb mediated terminal cell-cycle exit and expression of late myogenic genes (298). 
Lastly, Tip60, a MYST-related HAT, catalyzes Rb acetylation in order to control Rb 
expression levels (299). Collectively, evidence points to a new level of Rb regulation, and 
stability, caused by differential acetylation of the Rb protein. 
Protein acetylation is a reversible reaction. Interestingly, sirtuin 1 (SIRT1) not 
only deacetylates histones (300) but other non-histone proteins, such as p53 (301-303). A 
recent report by Wong and colleagues showed that Rb is a substrate for deacetylation by 
human SIRT1 (304). Their work showed that acetylated Rb increases in response to 
contact inhibition, and that over-expression of SIRT1 reduced the levels of Rb acetylation 
in vivo. They hypothesize that the active form of Rb is both acetylated and hypo-
phosphorylated, and that SIRT1-mediated deacetylation is required to deactivate Rb 
(304). Again, evidence points to the role of Rb acetylation as an activating event the may 
be required to promote its tumor suppressive functions. We have now shown that 
NORE1A can regulate the pro-senescent function of Rb via dephosphorylation. But since 
NORE1A has been shown to regulate multiple post-translational modifications of p53 in 
order for senescence to fully manifest itself, we hypothesize that a similar mechanism 
might be occurring with Rb, whereby NORE1A regulates both the phosphorylation and 
the acetylation of Rb. The regulation of acetylation could involve the modulation of 
acetyltransferases, such as PCAF and p300, as well as deacetylases such as SIRT1. 
 In addition to acetylation, Rb can be regulated by SUMOylation. Similar to 
ubiquitination, SUMOylation involves the covalent attachment of a small peptide moiety 
called SUMO (Small Ubiquitin-like Modifier) to specific lysine residues on a target 
protein that can have profound effects on protein function, from influencing protein-
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protein interactions to sub-cellular localization and protein stability (296). Though the 
significance of Rb SUMOylation remains somewhat undetermined, several studies have 
shown that hypophosphorylated Rb can be SUMOylated by SUMO-1 and by SUMO-2/3 
(305,306). The site of Rb SUMOylation was mapped to Lysine 720, and SUMOylation 
enhanced the ability of Rb to repress E2F transcription (305). In addition, the conjugation 
of SUMO can in some instances block the sites of attachment for ubiquitin, and can thus 
protect proteins from degradation (307). Therefore, it is plausible that the SUMOylation 
of Rb can promote its stability, raising the possibility that Rb can be both qualitatively 
and quantitatively regulated. We hypothesize that the SUMOylation of Rb is critical for 
its activation. Perhaps a reason why this fairly ubiquitous modification has only been 
recently identified and studied lies in the reversibility of the process and the fact that, 
apart from a very few exceptions, the amount of any SUMO-modified protein within a 
cell only makes up a very small percentage of its total amount, thus making detection by 
various molecular and biochemical methods more challenging (308). Because 
preliminary evidence in our laboratory suggested that Ras/NORE1A can affect the 
SUMOylation levels of proteins, such as HIPK2 (data not shown), we hypothesized that 
NORE1A may also be regulating the SUMOylation of Rb to activate Rb function. 
Protein inhibitors of activated STAT (PIAS) have been shown to function as E3 
SUMO ligases, and data from various SUMO conjugates make them one of the largest 
families of SUMO-specific ligases (309). The expression levels of one of the family 
member, PIASy, was shown to be significantly elevated during senescence when 
compared to pre-senescent cells, as do levels of hyper-SUMOylated proteins (310). In 
addition, over-expression of PIASy induces premature senescence, and this effect 
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requires its E3 SUMO ligase activity. More importantly, Ras-induced senescence was 
significantly delayed in PIASy
-/-
 MEFs, which was also reflected by their higher levels of 
hyperphosphorylated Rb (310). The study also showed that PIASy interacts with both 
p53 and Rb. The significance of these interactions was validated by the observation that 
the affinity for endogenous p53 and Rb for endogenous PIASy was significantly higher in 
bleomycin-induced senescent fibroblasts when compared to pre-senescent cells (310). 
Since NORE1A is a critical senescence effector of Ras, and preliminary evidence 
suggests that it can regulate the SUMOylation of proteins, it is plausible that NORE1A 
may be cooperating with PIASy to promote Ras-induced senescence. 
Here we show that NORE1A, in addition to promoting Rb activation by de-
phosphorylation, can also regulate other key post-translational modifications of Rb. Our 
evidence suggests that NORE1A enhances the overall acetylation as well as the 
SUMOylation of Rb, though the precise mechanisms are not fully defined. We show that 
NORE1A regulates Rb acetylation in a PCAF independent manner. Therefore, we 
hypothesize NORE1A mediated acetylation of Rb may be occurring via p300, as HIPK2, 
a binding partner of NORE1A, can recruit the acetyltransferase CBP/p300 into a complex 
to indirectly promote p53 acetylation (20,291). Thus, it is plausible that NORE1A can 
regulate Rb acetylation by a similar mechanism. We also show that NORE1A can 
enhance the SUMOylation of Rb. Though the mechanism by which NORE1A affects Rb 
SUMOylation remains unknown, we now show that NORE1A forms an exogenous 
complex with PIASy, one of the critical SUMO ligases involved in Ras-induced 
senescence. This finding does not confirm that PIASy is in fact the player involved in 
NORE1A enhanced Rb SUMOylation; however, it does bring up the intriguing 
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possibility that NORE1A could be regulating the SUMOylation of a number of proteins, 
as Rb is not the only target of PIASy. Lastly, we show that Ras and NORE1A cooperate 
to hyper-stabilize Rb, and that the loss of NORE1A leads to a decrease in overall Rb 
levels. Collectively, our results suggest that NORE1A regulates the post-translational 
modification code of Rb, just as is the case with p53, in order to drive its pro-senescent 
function, as well as stabilize the Rb protein, which highlights both a qualitative and 
quantitative means of NORE1A regulation of Rb. 
 
4.2 – Results: 
 
Ras/NORE1A enhance the acetylation of Rb – While the activity of Rb is 
currently thought to be primarily regulated by its phosphorylation status, Rb can also be 
regulated by acetylation (296-298,304). Since NORE1A can activate the pro-senescent 
function of p53 by altering its acetylation (20), we sought to determine if NORE1A could 
promote the acetylation of Rb. Overall levels of Rb acetylation can be studied by 
performing immunoprecipitations using Acetyl-Lysine conjugated beads followed by 
western blot analysis for the Rb protein. We observed that in transient transfections of 
HEK-293 cells, the over-expression of NORE1A and/or activated Ras promotes the 
overall acetylation of Rb (P<0.05), currently believed to be an activating event (Figure 
24). The levels of Rb acetylation were elevated in a similar manner in the presence of 
NORE1A and activated Ras when compared to Ras/NORE1A individually, likely 
because the acetylation machinery has been stimulated to maximum capacity by either 



















































































Figure 24. Ras/NORE1A enhance total Rb acetylation. A. HEK 293 cells were 
transfected with HA-NORE1A in the presence or absence of activated H-Ras for 24 
hours. Cells were lysed and equal amounts of protein were immunoprecipitated using 
acetyl-lysine conjugated beads. The immunoprecipitates were analyzed by western 
blotting with anti-Rb, HA, and KATE antibodies. B. Blots were quantified 
densitometrically to calculate the fold change in Rb acetylation normalized to total levels 
of Rb. *, P<0.05 compared to vector transfected cells. 
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 NORE1A forms an exogenous, Ras regulated complex with PCAF – While we 
have now shown that NORE1A can modulate the acetylation of Rb, it does not address 
the mechanism of action. Since NORE1A acts as a scaffolding molecule (20,194), we 
hypothesized that NORE1A could be interacting with one of the acetyltransferases 
known to regulate Rb acetylation, such as PCAF. We wanted to determine if NORE1A 
could be interacting with PCAF, one of the players involved in Rb acetylation (298). We 
co-transfected HEK-293T cells with NORE1A and PCAF in the presence or absence of 
activated Ras and found that NORE1A coimmunoprecipitated with over-expressed PCAF 
in a Ras dependent manner (Figure 25). 
 
 Ras/NORE1A modulate Rb acetylation in a PCAF-independent manner – Because 
we have shown that NORE1A can modulate the acetylation of Rb and interacts with 
PCAF, a known Rb acetyltransferase, we wanted to determine if the ability of NORE1A 
to enhance Rb acetylation was occurring via PCAF. We would anticipate that over-
expressing PCAF would enhance the ability of NORE1A to promote Rb acetylation. To 
address this, we co-transfected HEK-293 cells with NORE1A in the presence or absence 
of activated Ras and/or PCAF. Our results suggest that Ras/NORE1A enhance the 
acetylation of Rb in a PCAF-independent fashion (Figure 26), as the addition of PCAF in 
this system did not affect Ras/NORE1A mediated acetylation of Rb. 
 
 Ras/NORE1A enhances Rb SUMOylation – In addition to its regulation by 
phosphorylation and acetylation, recent evidence has now shown that Rb can be 

















Figure 25. NORE1A forms an exogenous, Ras regulated complex with PCAF. HEK-
293T cells were transfected with HA-NORE1A and FLAG-PCAF in the presence or 
absence of activated H-Ras for 24 hours. Cells were lysed and equal amounts of protein 
were immunoprecipitated for FLAG-PCAF, and the immunoprecipitates analyzed by 


















Figure 26. Ras/NORE1A enhance Rb acetylation in a PCAF-independent manner. 
HEK 293 cells were transfected with HA-NORE1A and FLAG-PCAF in the presence or 
absence of activated H-Ras for 24 hours. Cells were lysed and equal amounts of protein 
were immunoprecipitated using acetyl-lysine conjugated beads. The immunoprecipitates 
were analyzed by western blot using anti-Rb, HA, FLAG, and KATE antibodies. Results 





















Rb SUMOylation and its pro-senescent function. Since preliminary evidence from the 
laboratory had shown that NORE1A may be able to regulate the SUMO modification of 
other proteins, we sought to determine if NORE1A could be regulating the SUMOylation 
of Rb. To address this, we transiently transfected HEK-293T cells with GFP-Rb and HA-
SUMO-1 in the presence or absence of NORE1A and/or activated H-Ras. By 
immunoprecipitating with GFP-conjugated beads and western blotting for HA-SUMO-1, 
we can determine the levels of Rb-SUMOylation. Interestingly, our results suggest that 
Ras/NORE1A does enhance the SUMOylation of Rb. However, the levels of Rb 
SUMOylation were elevated in a similar manner in the presence of NORE1A and 
activated Ras when compared to Ras/NORE1A individually (Figure 27). This suggests 
that either the ability of NORE1A to enhance Rb SUMOylation might be Ras 
independent, or that the SUMOylation machinery has been stimulated to maximum 
capacity by NORE1A over-expression and therefore no further increase is possible. 
 
NORE1A forms an exogenous, Ras-regulated complex with PIASy – In order to 
elucidate a mechanism of action for NORE1A mediated SUMOylation of Rb, we wanted 
to identify potential SUMO ligases that interact with NORE1A, in turn allowing 
NORE1A to promote Rb SUMOylation. The most intriguing possibility is the protein 
PIASy, an E3 SUMO ligase that has previously been implicated in Ras mediated 
senescence (310). To determine if NORE1A interacts with PIASy, we co-transfected 
HEK-293T cells with FLAG-PIASy and HA-NORE1A in the presence or absence of 





















































































Figure 27. Ras/NORE1A enhance Rb SUMOylation. A. HEK-293T cells were 
transfected with GFP-Rb, HA-SUMO-1, and FLAG-NORE1A in the presence or absence 
of activated H-Ras for 24 hours. Cells were lysed and equal amounts of protein were 
immunoprecipitated using anti-GFP. The immunoprecipitates were analyzed by western 
blot using anti-HA, FLAG, GFP, and KATE antibodies. B. Blots were quantified 
densitometrically to calculate the fold change in Rb SUMOylation. *, P<0.05 compared 




a weak one; however, the results show that this interaction is enhanced in the presence of 
activated Ras (Figure 28), suggesting that this interaction is regulated by Ras. 
 
NORE1A co-localizes with Pc2 in nuclear speckles – Because the significance of 
protein SUMOylation has only recently been discovered, far less is known about the 
proteins involved in the SUMOylation machinery compared to other post-translational 
modifications. To date, there are few proteins that are known to act as E3 SUMO ligases 
in addition to the known PIASy. Interestingly, the Polycomb Group protein Pc2 is a 
SUMO E3 ligase that has recently been identified, and is found in a subnuclear structure 
(nuclear foci) called a Polycomb body (PcG bodies) (311). While Polycomb-group 
proteins have been shown to remodel chromatin, little is known about their function. 
Work done by David Wotton and colleagues suggests that Pc2 has a much more limited 
repertoire than other SUMO E3s, but bring up the possibility that Pc2 represents a 
specialized polycomb protein (312). In addition, they demonstrated that although it 
appears to have a relatively weak E3 in vitro, Pc2 has robust SUMO E3 activity in vivo 
(312), suggesting that its activity may be modulated by adaptor proteins. 
 Interestingly, recent evidence showed that Pc2 binds to HIPK2, and that these 
proteins have an overlapping localization in distinct nuclear speckles. Furthermore, Pc2 
serves as a SUMO E3 ligase for this kinase, and this SUMOylation was shown to 
enhance the ability of HIPK2 to mediate transcriptional repression (313). Because 
NORE1A was shown to regulate HIPK2 activity and is found in similar nuclear 
structures than the ones involving Pc2/HIPK2, we hypothesized that NORE1A might be 


























Figure 28. NORE1A forms an exogenous, Ras regulated complex with PIASy. HEK-
293T cells were transfected with HA-NORE1A and FLAG-PIASy in the presence or 
absence of activated H-Ras for 24 hours. Cells were lysed and equal amounts of protein 
were immunoprecipitated using anti-FLAG. The immunoprecipitates were analyzed by 




co-localization experiments using fluorescence microscopy. We transfected COS-7 cells 
with GFP-Pc2 and KATE-NORE1A in the presence or absence of activated Ras for 
24hours. Indeed, we found that in a vast majority of cells that expressed both proteins, 
NORE1A and Pc2 strongly co-localized in distinct nuclear speckles (Figure 29), 
suggesting that NORE1A might be regulating the SUMOylation of proteins through its 
association with Pc2. However, co-localization does not confirm protein-protein 
interaction, and thus must be validated by coimmunoprecipitation. Furthermore, the 
presence of activated Ras in a number of cells caused co-localization of NORE1A and 
Pc2 along the microtubule network, raising the possibility that Ras may be regulating the 
sub-cellular localization of Pc2 via NORE1A, potentially regulating the SUMOylation of 
additional proteins in addition to nuclear proteins. 
 
Ras and NORE1A cooperate to stabilize Rb – Post-translational modifications of 
proteins, such as acetylation and SUMOylation, have been shown to regulate protein 
stability (307,314). Since NORE1A forms an exogenous, Ras regulated complex with Rb, 
in turn modulating several key post-translational modifications of Rb, and because we 
found slightly elevated levels of Rb in the presence of Ras/NORE1A when performing 
experiments throughout this project, we hypothesized that Ras and NORE1A may be 
promoting the stability of Rb. To determine the effects of Ras and NORE1A on Rb 
stability, HEK-293 cells were transfected with Rb, NORE1A, and activated H-Ras 
expression constructs for 24 hours. The cells were then treated with cycloheximide and 
were lysed over a time course. The results show that after 8 hours following 






Figure 29. NORE1A co-localizes with Pc2 in the nucleus. COS-7 cells were 
transfected with GFP-Pc2 and RFP-NORE1A in the presence or absence of activated H-
Ras for 24 hours. Fluorescence microscopy analysis revealed that in some cells, 
exogenously expressed NORE1A forms nuclear speckles with Pc2, and that activated Ras 

















activated Ras (Figure 30). Furthermore, there is a consistent elevation of Rb expression 
in the presence of both NORE1A and activated Ras, suggesting that the proteins are 
cooperating to promote Rb stability. Further studies using a set of lung epithelial HBEC-
3KT cells, which we have engineered to be knocked down for NORE1A (20), showed 
that suppression of NORE1A acts to destabilize Rb levels (Figure 31). Collectively, 
these results suggest that Ras promotes Rb stability via NORE1A. 
 
4.3 – Discussion: 
 
 It has been well established that Ras, in addition to its ability to promote 
transformation, can induce cellular senescence (159). It is widely believed that such a 
mechanism acts as a critical barrier against tumor development. There is now over-
whelming evidence pointing to Ras being able to promote senescence through the critical 
p53 and Rb pathways, and that in human systems loss of both of these pathways is 
required in order for Ras to bypass senescence and promote transformation (169). 
However, the mechanisms by which Ras regulates p53 and Rb were not fully understood. 
 Interestingly, Ras was shown to promote the pro-senescent post-translational 
modifications of p53 (281), though how this was taking place remained unknown. It 
would seem logical that such tumor suppressive phenotypes would be occurring via 
senescence effectors of Ras. It was recently shown that NORE1A is a critical mediator of 
Ras-induced senescence. By forming a Ras regulated complex with HIPK2, NORE1A 
could scaffold HIPK2 to p53, in turn regulating the pro-senescent post-translational 
modifications of p53 (20). These findings provide two novel, and critical, lines of 














Figure 30. Ras/NORE1A cooperate to stabilize Rb. HEK 293 cells were transfected 
with HA-Rb and HA-NORE1A in the presence or absence of activated H-Ras for 24 
hours. The cells were treated with cycloheximide (20 µg/mL) and lysed at the indicated 
times after addition of cycloheximide. Levels of Rb protein were measured by western 
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Figure 31. Loss of NORE1A destabilizes Rb. A matched pair of HBEC-3KT cells 
containing either the scrambled shRNA control or two different NORE1A shRNAs were 
generated as previously described (20). Cells were lysed and equal amount of whole cell 































Ras regulates the post-translational modification signature of proteins, including tumor 
suppressors such as p53, via NORE1A. 
 The secondary pathway in Ras-induced senescence involves Rb, another tumor 
suppressor that, like p53, is primarily regulated by its post-translational modifications. 
We have shown that NORE1A can also promote Ras-induced senescence by regulating 
the Rb pathway. Ras can promote NORE1A mediated scaffolding of PP1A onto Rb in 
order to activate it via dephosphorylation. However, similar to p53, Rb is regulated by 
additional post-translational modifications. While the biological consequence of these 
modifications is not as clear as the phosphorylation events, the current evidence suggests 
that both the acetylation and SUMOylation of Rb as being activating events. 
 We have now shown that Ras and NORE1A enhance to overall acetylation of Rb. 
However, the mechanism of action remains unclear. Three proteins have been currently 
identified as being able to regulate Rb acetylation: PCAF, p300, and Tip60. Interestingly, 
we found that NORE1A forms an exogenous complex with PCAF; however, our over-
expression studies suggest that the ability of Ras/NORE1A to promote Rb acetylation is 
occurring in a PCAF independent manner. A previous report showed that acetylation of 
Rb at the C-terminus by p300 maintains Rb in its active, hypophosphorylated form (297). 
Interestingly, the kinase HIPK2 has been shown to recruit CBP/p300 to its effector 
proteins, such as p53, to regulate their function (291). Because we have previously 
established that NORE1A forms an endogenous, Ras regulated complex with HIPK2, in 
turn promoting the pro-senescent acetylation of p53 (20), it is possible that NORE1A can 
regulate Rb acetylation by a similar mechanism in order to maintain Rb in its active state.  
128 
 
 In addition to being regulated by phosphorylation and acetylation, Rb can also be 
modified by SUMOylation. SUMOylation of proteins is a relatively new concept, but one 
that has quickly shown to have drastic effects on protein function, such as protein 
stability and affecting protein-protein interactions. While the site for Rb SUMOylation 
has been mapped to Lysine 720 (305), the significance of this modification remains 
poorly understood. Interestingly, the SUMOylation machinery has been linked to 
senescence, as processed forms of SUMO-2/3 promotes senescence in a p53 and Rb 
dependent manner (306). Because the link between Rb, SUMOylation, and senescence is 
quite unclear, and that prior evidence from our laboratory showed that NORE1A could 
modulate the SUMOylation of other proteins, we believed that NORE1A might be 
regulating Rb SUMOylation. Indeed, over-expressing Ras/NORE1A did lead to an 
increase in the levels of Rb SUMOylation. What remains unknown is the mechanism by 
which NORE1A regulates this Rb modification. Currently, there are two intriguing 
possibilities that have arisen from our preliminary findings. First, we have shown that 
NORE1A forms an exogenous, Ras regulated complex with the E3 SUMO ligase PIASy, 
which is already established to play a role in Ras mediated senescence. Furthermore, we 
have shown that NORE1A strongly co-localizes with the newly identified E3 SUMO 
ligase Pc2, a protein known to regulate HIPK2 SUMOylation, and that activated Ras 
seems to affect some of this co-localization to the microtubule network in addition to 
nuclear speckles. While both of these potential mechanisms are quite interesting, there is 
a substantial amount of work that will need to be performed in order to confirm that one 
of these pathways is indeed the mechanism of action for NORE1A mediated Rb 
SUMOylation. Even with the possibility of NORE1A regulating Rb SUMOylation 
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independently of these potential pathways, the data strongly implicates NORE1A with 
the SUMOylation machinery, raising the intriguing possibility that NORE1A could be 
mediating the function of a variety of unknown target proteins via SUMOylation. 
 In addition to being regulated at a qualitative level by post-translational 
modifications, Rb can also be regulated from a quantitative perspective, as it has been 
shown to be degraded through a proteasome-dependent pathway (315,316). It was later 
found that the ubiquitin ligase mdm2 promotes Rb protein degradation via a proteasome-
dependent pathway (286). We have now shown that Ras and NORE1A cooperate to 
stabilize Rb protein, and that the loss of NORE1A destabilizes Rb. NORE1A has been 
shown to associate with mdm2 to regulate the stability of other targets (288). Thus, it 
would be interesting to determine if NORE1A could be stabilizing Rb by antagonizing 
the effects of mdm2 on Rb. In addition, one  of the physiological functions of protein 
SUMOylation is that it can regulate protein stability (307). Thus, the ability of 
Ras/NORE1A to modulate Rb stability might come for the ability to enhance Rb 
SUMOylation. It would be interesting to determine if generating a SUMO-deficient Rb 
mutant (via site-directed mutagenesis) would show a decrease in stability, even in the 
presence of Ras/NORE1A. In parallel, it would also be intriguing to determine what the 
outcome of such a mutant might have on NORE1A mediated senescence. However, it is 
quite possible that SUMOylated Rb may serve to regulate different Rb functions in 
addition to senescence, which may explain why Rb is such a critical tumor suppressor as 
well as the reason for its inactivation in such a high percentage in human cancers. 
 It has been well established that Ras can regulate critical signaling cascades by 
phosphorylation and dephosphorylation events (108), suggesting that this may be the 
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fundamental mechanism by which Ras modulates its effector proteins. However, we have 
recently described a novel mechanism by which Ras, through its effector NORE1A, can 
regulate the acetylation of p53 to induce senescence (20). This was the first description 
showing that Ras can regulate protein acetylation. Furthermore, we now show evidence 
suggesting that Ras can also regulate Rb acetylation via NORE1A. Therefore, it is 
reasonable to suggest that Ras mediated protein acetylation may be just as important, if 
not more important, than phosphorylation. Indeed, recent proteomics analysis has 
identified thousands of acetylated mammalian proteins, which has now given rise to the 
“in vivo acetylome” (317). More importantly, a large number of the acetylation sites 
identified were present on proteins involved in numerous, vital biological processes, such 
as chromatin remodeling, DNA replication, and nuclear transport, suggesting that these 
processes may be influenced by such a modification (317). Thus, from a clinical 
standpoint, a true understanding of how Ras regulates the “acetylome” will be critical in 
terms of evaluating the proper therapeutic approaches for cancer treatments. This is of 
particular interest with regards to targeting HDACs or SIRTs using pharmacological 
approaches. For example, SIRT1 is over expressed in some cancers harboring Ras 
mutations, and targeting SIRT1 has been shown to suppress transformation and sensitize 
such cancers to conventional therapy (318). Mechanistically, SIRT1 mediated 
deacetylation suppresses the functions of several tumor suppressors, including p53 (302). 
Additionally, HDAC inhibitors are another class of anti-cancer agents that are cytotoxic 
to cancer cells, and some studies have shown that HDAC inhibitors can activate the pro-
apoptotic ability of oncogenic Ras (319). Ultimately, it will be of utmost importance to 
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determine the expression patterns of Ras effectors that play a role in the regulation of the 
“acetylome” in order to optimize therapeutic options targeting the acetylation machinery. 
 Lastly, our data highlights the first example by which Ras can promote the 
SUMOylation of proteins. Here, we show that by using its effector NORE1A, Ras can 
promote the SUMOylation of Rb, and may be doing so in part by promoting the 
interaction of NORE1A with SUMO ligases. While much less is known about protein 
SUMOylation compared to other post-translational modifications, the SUMOylation 
machinery has now been implicated in several important biological processes, such as the 
onset of cellular senescence (307). Collectively, these findings suggest a potential 
paradigm shift for Ras action. While it has been clearly shown that Ras regulates several 
key signaling pathways by modulation of protein phosphorylation, it now seems as if Ras 
can regulate additional post-translational modifications that may be just as critical in 














 Collectively, the work presented in this dissertation highlights a novel mechanism 
that explains an unanswered question: how does Ras regulate Rb? It has been known for 
over thirty years that while Ras can be powerfully transforming, it can also regulate 
growth inhibitory pathways. While it has now been clearly established that Ras can 
induce senescence, primarily by activating p53 and Rb, how Ras specifically regulates 
the p53 and Rb pathways remained unknown. Our work shows that Ras uses NORE1A as 
a senescence effector to regulate powerful tumor suppressors, p53 and Rb, that play 
crucial roles in Ras mediated senescence. 
We found that NORE1A forms an endogenous, Ras regulated complex with the 
phosphatase PP1A. Not only does NORE1A stabilize PP1A, it scaffolds PP1A to Rb in a 
Ras dependent manner, in turn activating Rb via dephosphorylation. Furthermore, we 
show that NORE1A requires Rb in order to fully promote senescence. These findings, 
along with previous work performed in the laboratory, define NORE1A as a double 
barreled senescence effector of Ras by regulating pro-senescent post-translational 
modifications of p53 and Rb (Figure 32). Loss of NORE1A subverts these two critical 






Figure 32. Molecular mechanisms whereby Ras promotes the induction of 
senescence via its effector NORE1A. In normal cells, Ras promotes the acetylation of 
p53 via the NORE1A/HIPK2 as well as the dephosphorylation of Rb via the 
NORE1A/PP1A axis. Together, these pathways serve as a protective barrier against 
unrestricted Ras mediated transformation. In the absence of NORE1A (right), the pro-
senescent functions of p53 and Rb cannot be activated, resulting in the bypass of 
senescence induction and allows for the Ras mediated proliferative signals to dominate. 
Ac, acetylated lysine; P, phosphorylation. 
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turn driving Ras towards transformation. This validates previous findings showing that 
Ras driven tumors are frequently associated with reduced NORE1A expression. 
Interestingly, PP1A is not an Rb-specific phosphatase, and can modulate the 
function of proteins by regulating their phosphorylation status. The specificity of PP1A 
for its substrates is dictated by other targeting proteins. Indeed, PP1A can associate with 
over two hundred regulatory proteins which can dephosphorylate hundreds of targets. 
Our data shows that NORE1A may serve as a PP1A targeting protein. However, our 
work has not confirmed whether the NORE1A/PP1A complex specifically targets Rb. 
Further experiments will be vital to determine any additional NORE1A targeted 
substrates. 
 In addition to regulating Rb phosphorylation, we found that NORE1A can 
regulate additional post-translational modifications of Rb, including acetylation and 
SUMOylation. Unlike phosphorylation, the significance of Rb acetylation/SUMOylation 
remains poorly understood; however, it is believed that these modifications are activating 
events. It will be interesting to determine if these modifications are necessary for Rb 
mediated senescence. There is some belief that Rb modifications, such as SUMOylation, 
may actually lead to a specific sub-set of Rb protein that perform distinct Rb functions in 
addition to the prototypical cell cycle arrest and senescence induction. 
 This work highlights novel mechanisms by which Ras can regulate protein 
acetylation as well as SUMOylation, suggesting the need for a new paradigm for Ras 
action. It has been well established that Ras can regulate the function of proteins by 
modulating their phosphorylation status. However, our evidence strongly suggests that in 
addition to such regulation, Ras can regulate multiple post-translational modifications by 
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using its effector proteins, such as NORE1A, to target specific substrates. Therefore, Ras 
must be thought of as a critical mediator of protein function by playing a pivotal role in 
regulating the post-translational modification code of downstream proteins, including the 
previously unidentified modifications of acetylation and SUMOylation. 
 Throughout the project, we found that Ras/NORE1A stabilize both PP1A and Rb. 
These findings were not unexpected for several reasons. First, we had previously shown 
that NORE1A can affect the stability of other proteins, such as HIPK2 (20). Second, it 
seems logical that if NORE1A is a senescence effector of Ras, it would stabilize the 
PP1A/Rb complex in order to activate the pro-senescent functions of Rb. While these 
findings are interesting, they do not provide a mechanism of action. Future studies are 
crucial to determine the mechanisms by which NORE1A promotes the stability of PP1A 
and Rb. One attractive possibility is via the ubiquitin ligase mdm2, for two reasons. First, 
mdm2 has been shown to promote tumorigenesis by destabilizing Rb. Second, mdm2 has 
been found in an endogenous complex with PP1A. Intriguingly, NORE1A has been 
implicated in regulating the degradation of specific mdm2 targets. Thus, NORE1A could 
be promoting the stability of both PP1A and Rb by antagonizing the degradation 
properties of mdm2. 
 Some standard therapies invoke a senescence response as part of their therapeutic 
effect. Indeed, the concept of pro-senescence therapy has emerged over the recent years 
as a novel therapeutic approach to treat cancers, and it is now believed that the inclusion 
of deliberate pro-senescence therapy may be critical as part of cancer treatment regimens 
(320). Such approaches include drugs that enhance p53 activity and function, as well as 
drugs with the ability to modulate Rb activity through targeting Cdks and CDKIs (320). 
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Our studies here indicate that the status of NORE1A in a tumor may play a role in 
dictating the sensitivity of tumor cells to any pro-senescence type therapy. 
 As loss of NORE1A expression primarily occurs via promoter methylation, it is a 
candidate for epigenetic therapy. It has already been shown that restoring NORE1A 
expression in several NORE1A-negative cancer cell lines using the DNA methyl-
transferase inhibitor 5-Azacytidine restores NORE1A signaling pathways (191). 
Unfortunately, treatment with 5-Aza-C results in non-specific overall DNA methylation 
and this process may affect multiple regulatory pathways (321). This can likely reactivate 
expression of multiple silenced genes, including oncogenes and tumor suppressors in 
different cell types and in different cancers (322). However, the continued development 
of more specific epigenetic therapy agents, such as Nanaomycin A, which preferentially 
inhibits the key DNMT3B enzyme, may enhance the practicality of this approach. Recent 
evidence has shown that Nanaomycin A reduced global methylation levels while 
reactivating transcription of several RASSF family members (323,324), though its effects 
on NORE1A expression have not yet been studied. Thus, a novel approach in NORE1A 
negative cancers might be to combine epigenetic therapy with senescence therapy to 
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